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ABSTRACT  99 
 100 
Pro-opiomelanocortin (POMC) is the archetypal polypeptide precursor of 101 
hormones and neuropeptides. In this review, we examine the variability in the 102 
individual peptides produced in different tissues and the impact of the 103 
simultaneous presence of their precursors or fragments. We also discuss the 104 
problems inherent in accurately measuring which of the precursors and their 105 
derived peptides are present in biological samples. We address how not being 106 
able to measure all the combinations of precursors and fragments quantitatively 107 
has affected our understanding of the pathophysiology associated with POMC 108 
processing. To understand how different ratios of peptides arise, we describe the 109 
role of the pro-hormone convertases (PCs) and their tissue specificities and 110 
consider the cellular processing pathways which enable regulated secretion of 111 
different peptides that play crucial roles in integrating a range of vital 112 
physiological functions. In the pituitary, correct processing of POMC peptides is 113 
essential to maintain the hypothalamic-pituitary-adrenal axis and this processing 114 
can be disrupted in POMC expressing tumours. In hypothalamic neurons 115 
expressing POMC, abnormalities in processing critically impact on the regulation 116 
of appetite, energy homeostasis and body composition. More work is needed to 117 
understand whether expression of the POMC gene in a tissue equates to release 118 
of bioactive peptides. We suggest that this comprehensive view of POMC 119 
processing, with a focus on gaining a better understanding of the combination of 120 
peptides produced and their relative bioactivity, is a necessity for all involved in 121 
studying this fascinating physiological regulatory phenomenon.   122 
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I.  INTRODUCTION 148 
 149 
A.  The Discovery of POMC as a Precursor  150 
The phenomena of POMC as a hormone precursor emerged gradually over time 151 
as observations slowly filled in pieces of the puzzle. Long before the concept of 152 
hormone precursors was realized, the bronzed skin color described by Addison 153 
in his patient with adrenal insufficiency (“melasma suprarenale”) gave perhaps 154 
the first hints of a connection between the hypothalamic, pituitary, adrenal 155 
(HPA) axis and skin colour. A similar link between the pituitary and 156 
pigmentation came from the studies of Allen and Smith (5, 376) who both noted 157 
that immersing tadpoles in pituitary extract made their skins darker. In humans 158 
too, large doses of porcine pituitary extract also appeared to cause pigmentation 159 
(218), with this active extract of the pars intermedia of the pituitary henceforth 160 
termed “melanocyte stimulating hormone” or MSH.   161 
 162 
In 1932, Cushing extended his clinical reports of a polyglandular syndrome 163 
caused by basophilic adenomas of the pituitary by linking this finding with 164 
adrenal hyperactivity. In the 1930’s work by Ingle and Kendall (177) showed 165 
that administration of large amounts of “cortin” , a purified adrenal extract, 166 
produced atrophy of the adrenal cortex in rats. Importantly they found that 167 
administration of the “adrenotropic principle” of the anterior pituitary was 168 
effective in preventing adrenal cortical regression following treatment with 169 
cortin. The first hints of a behavioural angle to pro-opiomelanocortin (POMC) 170 
biology came from studies by Ferrari in the 1950s, when “stretching-yawning 171 
syndrome” – a bizarre crisis of muscular tone - occurred following central 172 
administration of MSH. Many other studies assessing the effects of central -MSH 173 
on motivational processes followed but it was not until 1976 that Panskepp 174 
observed for the first time that this peptide decreased food intake (294).  175 
 176 
Viewed from the comfort and assured knowledge of the modern molecular world 177 
these observations and interventions could be considered overtly simplistic. 178 
However we believe that these classic observations should be regarded as 179 
essential building blocks not only for our understanding of POMC peptide 180 
processing but also for the work which subsequently tied together these 181 
seemingly diverse peptides. 182 
 183 
B.  The emergence of the precursor paradigm 184 
 185 
It is likely that POMC arose over 500 million years ago by an insertion of the 186 
melanocortin sequences into a prepro-endorphin gene. Evidence for this comes 187 
from structural identities with other opioid precursors in both the N- and C-188 
terminal regions of POMC (266). The common opioid gene was thought to arise 189 
during chordate evolution. There are four opioid genes which are on three 190 
chromosomes in the vertebrate genome. An intragenic duplication event in 191 
tetrapods is thought to have led to the presence of -MSH, -MSH and γ-MSH 192 
(265). The -MSH sequence is not present in teleosts and is found as a vestige in 193 
non-teleosts, whereas an additional melanocortin peptide, termed δ-MSH has 194 
been found in cartilaginous fish. This suggests a divergence in MSH sequences in 195 
cartilaginous, ray and lobe-finned fish (266). 196 
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 197 
The golden age for the precursor paradigm came in the 1960s and 1970s 198 
particularly when the first evidence for a precursor of insulin was unearthed by 199 
Don Steiner and his team (382, 383). Sequencing confirmed the existence of pro-200 
insulin in 1968 (60) and subsequently pro-insulin was shown to be relatively 201 
less active compared to insulin (202). This inspiring work by Don Steiner paved 202 
the way for a much greater understanding of a whole range of pro-hormones 203 
particularly in relation to their processing. 204 
 205 
High molecular weight forms of ACTH and -LPH:  Although 206 
adrenocorticotropic hormone (ACTH) and -lipotropin (-LPH) had been 207 
characterized separately, the concept that they were produced as part of a 208 
common precursor had not been considered and only emerged after a number of 209 
different approaches suggested the sequences for these different peptides in the 210 
same molecule (Figure 1) (reviewed in (66, 280)). Elegant studies by Yalow and 211 
Berson (433) using normal human pituitary extracts and an ectopic ACTH 212 
producing thymoma, indicated that ACTH was present in a high molecular 213 
weight form. These high molecular weight forms of ACTH were also identified in 214 
the mouse pituitary tumor cell line, AtT20 (119, 232). Lowry et al. (230) went on 215 
to use human pituitary extracts and precipitated a single pro-hormone using 216 
antibodies to the different peptides (228). This was made possible because 217 
previous work by Chrétien and Li (65) had discovered that the -LPH sequence 218 
was found within -LPH and that it had the -MSH sequence at its C-terminal. 219 
This led them to propose a pro-hormone theory (reviewed in (66)). The presence 220 
of an opioid peptide at the C-terminal of -LPH was a serendipitous finding by 221 
Hughes et al. (173) when they identified the met-enkephalin sequence at the N-222 
terminal of -endorphin in the -LPH molecule. This was confirmed by the 223 
sequencing of -endorphin (154). 224 
 225 
Figure 1: Processing of POMC in different tissues 226 
 227 
In 1978, the concept that POMC was a pro-hormone for ACTH and -LPH was 228 
confirmed in studies with the ACTH-secreting AtT20 cell line. Mains et al. 229 
radiolabeled amino acids in the cells and then used immunoprecipitation and 230 
SDS gel electrophoresis, enabling them to identify a 31Kd peptide recognized by 231 
antibodies to both ACTH and -LPH (234). Roberts and Herbert utilized a similar 232 
approach but with cell-free translation and antisera to both peptides and 233 
reported similar results (329). 234 
 235 
The emergence of the full structure of POMC: Not long after these studies, the 236 
precursor peptide was purified from rat pituitaries (335) and (rather strangely) 237 
from camel pituitaries (200). Michel Chrétien and Nabil Seidah then named the 238 
precursor, pro-opiomelanocortin to reflect the known roles of the peptides in the 239 
precursor (64). The same year, cloning cDNA from pituitary pars intermedia 240 
provided the gene sequence for bovine POMC (265) which was independently 241 
confirmed by protein sequencing (264). Similar approaches identified the 242 
sequences for the human (72, 391), mouse (407), rat (105) and pig (38) genes 243 
(69). Despite the sequence being highly conserved, there is some variation in the 244 
lengths of some of the peptides in different species (Figure 2). This led to 245 
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confusion when numbering the amino acids from the N-terminal of POMC as the 246 
amino acids in the smaller peptides were given different nomenclatures 247 
depending on the species (Figure 2).  Nevertheless the structure of the gene itself 248 
is well conserved, especially in the regions covering the biologically active 249 
peptides including ACTH, -MSH and -endorphin (165). Importantly, there are 250 
a few key species differences which affect the processing and this will be covered 251 
in section II E after the details of processing have been described.  252 
 253 
Figure 2: POMC protein sequence in different species 254 
 255 
C. The tissue localization of POMC 256 
 257 
There is a wealth of evidence that in a few key tissues, where both the POMC 258 
gene is expressed and peptides derived from the POMC precursor protein are 259 
released, POMC has an important and biologically meaningful role. These include 260 
the pituitary, the arcuate nucleus of the hypothalamus, the nucleus tractus 261 
solitarius, and the skin.  However the POMC gene has been reported to be widely 262 
expressed throughout the body including in the testis (94, 151, 211, 309), ovary 263 
(62, 94), placenta (62), spleen (94), lung (94, 183), liver (94), thymus (183, 211), 264 
thyroid (94, 183), heart (253), kidney (94), lymphocytes (275), duodenum (94, 265 
183), colon (94) and adrenal gland (94, 183, 211). Many of these studies were 266 
carried out using techniques such as northern blot and PCR and show 267 
expression, but not whether translation to the protein or processing occurs in 268 
these locations. In fact, it has been shown that many of these tissues contain a 269 
shorter mRNA transcript which would not be translated and therefore no 270 
peptide produced (69). Furthermore, in both humans and murine models lacking 271 
POMC, no obvious phenotypes relating to these diverse tissues have been 272 
reported. Therefore, even if active POMC peptides were made in these tissues, 273 
their functional significance would appear to be negligible.  274 
 275 
The use of the POMC-Cre mouse line expressing a fluorescent protein has further 276 
confused our understanding of the expression patterns of POMC, especially in 277 
brain regions. POMC is widely expressed during development but this becomes 278 
more restricted in adulthood. However, the POMC-Cre manipulation will allow 279 
fluorescent protein to continue to be expressed in adulthood, even if POMC was 280 
only expressed in that particular region during a developmental period. This was 281 
first highlighted in the arcuate nucleus of the hypothalamus, where AgRP/NPY 282 
and POMC neurons are mutually exclusive in adulthood. However, the AgRP/NPY 283 
neurons expressed the POMC-Cre lineage in adulthood, although they did not 284 
continue to express POMC at this time (283). The same group carried out a 285 
further study using the POMC-Cre line examining other brain regions and found 286 
POMC recombination in regions including the hippocampus, regions of the cortex 287 
and midbrain (284). Peripheral tissues have not been examined, but this same 288 
extopic pattern may be true for POMC expression outside the brain. 289 
Furthermore, using the POMC-Cre mouse line to excise genes in POMC 290 
expressing tissues may lead to spurious deletion in other regions where it may 291 
not be truly relevant. 292 
 293 
Expression the POMC gene is only one facet of a complex mechanism which 294 
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requires coordinate release of POMC protein and processing enzymes to 295 
generate a biologically relevant effect. We have concentrated on the pituitary, the 296 
hypothalamus, and skin where there is evidence for all these processes and for 297 
the roles of the peptides produced from these tissues. 298 
 299 
 300 
II.  OVERVIEW OF POMC PROCESSING 301 
 302 
POMC is cleaved by pro-hormone convertases (PCs) at well-defined dibasic 303 
amino acid sequences. The type of pro-hormone convertase in a particular tissue 304 
defines the specific peptides produced. There is no doubt that the processing of 305 
pro-hormones is a very specific mechanism but why this is necessary has not 306 
been addressed in detail in this review (Figure 1). 307 
 308 
Figure 1: Processing of POMC in different tissues 309 
 310 
In the anterior pituitary, POMC is initially cleaved between the C-terminal of 311 
ACTH and the N-terminal of -LPH (119) to yield pro-ACTH and -LPH. This 312 
cleavage is carried out by pro-hormone convertase 1/3 (PC1/3) which cleaves at 313 
sites where there are dibasic amino acids. In this case, the cleavage is at the Lys-314 
Arg site at the C-terminal of ACTH. There are other dibasic amino acid sequences 315 
in POMC indicating that any preference for cleavage at one site over another is 316 
most likely due to neighbouring amino acids or the resultant 3D structure 317 
allowing easier access to the active site of the convertase. 318 
 319 
The next stage in cleavage occurs between the C-terminal of joining peptide and 320 
the N-terminal of ACTH. This releases ACTH and an N-terminal peptide 321 
containing N-POMC (also called pro- MSH) and joining peptide. The latter was 322 
discovered as the “missing fragment” in human POMC in 1981 (354). The human 323 
joining peptide is amidated and secreted as a homo-dimer, joined by a cysteine 324 
bridge (25). In humans it is thought that there is relatively little further 325 
processing in the anterior pituitary. This would result in N-POMC, joining 326 
peptide, ACTH and -LPH as the major POMC-derived peptides released from the 327 
anterior pituitary. 328 
 329 
A.  Generation of MSH peptides 330 
 331 
In the hypothalamus and pars intermedia of the anterior lobe of the pituitary 332 
(present in rodents and human fetal pituitaries, but rudimentary in adult 333 
humans), there is much more extensive processing of POMC. Again, the degree of 334 
processing is determined by which enzymes are expressed in the different 335 
tissues.  336 
 337 
 338 
B.  Generation of -MSH from ACTH  339 
  340 
Generation of -MSH initially involves cleavage of ACTH by PC2 to give ACTH (1-341 
17) and corticotrophin-like intermediate lobe peptide (CLIP), which represents 342 
ACTH (18-39) (Figure 1). To generate -MSH from ACTH (1-17), C-terminal 343 
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amino acids are removed in a step-wise fashion by carboxy-peptidase E (CPE). 344 
Disruption to the activity of this enzyme has major consequences for processing 345 
(described later in Section VI). ACTH (1-13) is then amidated at the C-terminal 346 
by peptidyl-glycine -amidating monooxygenease (PAM) to give ACTH (1-13)-347 
NH2, which is also known as des-acetyl -MSH. This is then acetylated at the N-348 
terminal by N-acetyl transferase (N-AT) to give -MSH (152). The main effect of 349 
N-terminal acetylation is not obvious (261) as some functions are increased and 350 
others are blocked by this process. For instance, -MSH is more potent in 351 
modulating pigmentation, memory and attraction, whereas des-acetyl -MSH is 352 
more effective in blocking opiate analgesia (49, 273). 353 
 354 
C.  Generation of -MSH and -Endorphin from -LPH  355 
 356 
-LPH is processed initially by cleavage of the amino acids between the C-357 
terminal of -lipotropin (-LPH) and the N-terminal of -endorphin (Figure 1). -358 
LPH can then be processed at a Lys-Lys site to release -MSH from its C-terminal. 359 
This Lys-Lys site is present in the human POMC sequence but not in that of rats 360 
or mice and therefore it is thought that -MSH does not exist as a separate 361 
peptide in rodents (114).  362 
 363 
The sequence of -endorphin is the 31 amino acids at the C-terminal of POMC. 364 
The initial processing of POMC may only yield -LPH, however cleavage can 365 
continue to give -endorphin within the secretory granules before release from 366 
some pituitary corticotropic cells (439). Several studies have shown that in 367 
addition to -endorphin (1-31) some further processing can occur to give -368 
endorphin (1-27) and -endorphin (1-26) which are also present in pituitary and 369 
brain.  370 
 371 
D.  Generation of -MSH from N-POMC  372 
 373 
The N-terminal region of POMC contains the sequence for the third melanocortin 374 
peptide -MSH (Figure 1). Pro--MSH is often called N-POMC or N-POC (1-76 in 375 
humans and 1-74 in rat and mouse). In the human N-POMC sequence there is a 376 
pair of dibasic amino acids at 49/50 which would enable enzymatic cleavage to 377 
N-POMC (1-49) and 3-MSH (also known as Lys-3-MSH) which has 27 amino 378 
acids. From the gene sequence, 3-MSH was not expected to include the first 379 
lysine, but the cleavage takes place at the C-terminal side of the arginine residue 380 
leaving lysine as the first amino acid in 3-MSH (29). As it is an extension to the 381 
predicted sequence it is sometimes included in the nomenclature. Further 382 
processing occurs to produce the 2-MSH sequence which is a dodecapeptide and 383 
then this can be cleaved to the 11 amino acid 1-MSH. However this processing 384 
can be restricted by glycosylation at Asn16 in 3-MSH (32).  385 
 386 
E.  Species Differences in POMC processing 387 
 388 
Many of the melanocortin peptides are conserved among mammalian species, 389 
although there are some exceptions, which have consequences for physiology 390 
(Figure 2). Neither rats nor mice are able to produce -MSH, as they lack the 391 
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dibasic residues required for cleavage at their N-terminal region (16). For guinea 392 
pigs there is speculation that they may also have a shorter version of -MSH, as 393 
they have 2 sets of dibasic residues in the C-terminal region, which could 394 
potentially give rise to 2 variations of -MSH (113). 395 
 396 
In mouse, rat and guinea pig, 1- or 2-MSH may not exist because the C-terminal 397 
region does not have the dibasic amino acids to allow cleavage (113). This would 398 
suggest that rodents only have the extended 3-MSH peptide whereas in the 399 
human POMC sequence the 1-MSH peptide has flanking dibasic amino acids and 400 
therefore the potential for cleavage (Figure 2).  401 
 402 
 403 
III.  ENZYMES INVOLVED IN PROCESSING POMC TO DIFFERENT PEPTIDES 404 
 405 
The very specific processing pathway for peptide hormones enables enzymatic 406 
cleavage of the precursors in a defined environment. While a lot is known about 407 
the pro-hormone convertases and the cleavage of pro-insulin, many of the 408 
mechanisms involving these cleavage processes were identified by studying the 409 
processing of POMC. In addition, there are a number of other enzymatic 410 
modifications which occur in the processing pathways to prepare the hormones 411 
for their roles (Figure 1). 412 
 413 
A.  Pro-hormone convertases (PCs) 414 
 415 
The pro-hormone convertases (PCs) are a family of serine proteinases of the 416 
subtilisin/kexin type and although PC1/3 and PC2 are the most important for 417 
POMC processing, studies on PC4, PACE4, PC5/6, PC7, S1P/SKI-1 and PCSK9 418 
have informed our knowledge of the mechanisms of proprotein processing. Much 419 
of the early work on the convertases has been reviewed by Bergeron et al. 420 
(2000), Seidah and Chretien (1999), Seidah (2011) and Chretien and Mbikay 421 
(2016) (22, 66, 349, 351). 422 
 423 
The subtilisin endoproteases are highly homologous to human furin. These 424 
proteases are calcium dependent and cleave at single or dibasic amino acids. The 425 
cleavage occurs at the C-terminal of the pair of dibasic amino acids. In POMC the 426 
Lys-Arg (KR) site at the C-terminal of ACTH is cleaved first and then the Lys-Arg 427 
at the N-terminal of ACTH. The Lys-Lys-Arg-Arg site in ACTH which is cleaved to 428 
give ACTH (1-17) in the processing to -MSH is not cleaved in human anterior 429 
pituitary corticotropes. This provides evidence that the adjacent amino acids 430 
influence the ability of the PCs to identify the cleavage sites. These types of 431 
cleavage sites are found in most peptide hormones and neuropeptides. It is 432 
thought that Arg-Lys and Lys-Lys sites are cleaved very slowly over days and this 433 
occurs only in melanotropes and not in corticotropes.  434 
 435 
1. PC1/3 and PC2: How they got their names 436 
 437 
Although POMC was identified as the precursor of ACTH and -LPH in 1977 (235, 438 
329), it took 15 years to discover the enzymes which cleave the peptides from 439 
POMC (reviewed in (66)). It was the identification of the yeast protease Kex2 440 
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that led to the breakthrough. The kex2-like subtilisins have similar catalytic 441 
mechanisms to trypsin-like proteases. This led to the identification of a human 442 
insulinoma cDNA encoding a pro-hormone convertase subsequently named PC2 443 
(375). At about the same time a second group published the sequence of a mouse 444 
pro-hormone convertase which they referred to as PC1 (352). Smeekens and 445 
Steiner then isolated cDNA from the human insulinoma encoding a similar 446 
convertase and this convertase they named PC3 (374). This turned out to be 447 
identical to PC1, such that the nomenclature is now PC1/3.  448 
 449 
2. Active pro-hormone convertases are cleaved from inactive precursors 450 
 451 
All pro-hormone convertases are themselves derived from precursors and are 452 
trafficked to the secretory granules where POMC processing occurs. The 453 
maturation of PC1/3 from its precursor is described by Stijnen et al (387). PC1/3 454 
has a signal peptide and an 80-90 amino acid prosegment at the N-terminal. The 455 
prosegment is thought to act as an intramolecular chaperone and a competitive 456 
inhibitor of the active site of the enzyme. In the endoplasmic reticulum, the 457 
inhibitory prosegment is removed by an autocatalytic process. A similar 458 
mechanism occurs for PC1/3 (153). 459 
 460 
The precursor protein seems to act as a competitive inhibitor at the active site of 461 
the processed PC. In particular, Pro-PC1/3, expressed in its trans-conformation, 462 
is able to act as an inhibitor of PC1/3 (215). The prosegments of PCs may have 463 
inhibitory actions which are distinct for each PC, as they are different in each PC 464 
precursor (40).   465 
 466 
After the prosegment of PC1/3 is proteolytically removed, which takes several 467 
minutes (446), the resulting 84kDa pro-hormone convertase moves to the trans 468 
Golgi network (TGN) and then to immature secretory granules (ISGs) where a C-469 
terminal inhibitory peptide (185) is removed. This leaves a 66 kDa form which is 470 
much more active than the 84 kDa form (447). This C-terminal peptide has to be 471 
cleaved by PC1/3 in the ISGs to stop its inhibitory action on the catalytic domain, 472 
so that the mature 66 kDa form is fully active to cleave its target peptides. This 473 
suggests that the post-translational processing of the PCs is regulated very 474 
precisely. Too much active PC1/3 in the ER would generate the fully active form, 475 
but without some autocatalytic activity the inhibitory forms would not be 476 
removed. The C-terminal domain is also important for directing PC1/3 into 477 
secretory granules; without this the 66 kDa form would move to the constitutive 478 
pathway (350). 479 
 480 
3. Activation of PC2: the role of 7B2 481 
 482 
PC2 is also synthesized as part of a precursor but is processed within the TGN 483 
and ISG. There is a very distinct mechanism for activation of PC2, which takes 1-484 
2h and provides the delay necessary for the correct stages of processing 485 
(reviewed in (393)). PC2 has a specific binding protein, 7B2, which is required 486 
for transport, folding and activation of PC2 (22). The N-terminal of 7B2 has a 487 
chaperone function while the C-terminal of 7B2 inhibits PC2 (136). 7B2 is 488 
thought to bind to the catalytic domain of PC2 and is required for the efficient 489 
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transport and activation of the enzyme (350). 7B2 and pro-PC2 form a complex 490 
in the endoplasmic reticulum (ER) and this enables trafficking to the TGN, where 491 
7B2 is cleaved by furin. The C-terminal of 7B2 then binds pro-PC2 and acts as an 492 
inhibitor. As the complex is trafficked into the immature secretory granules, the 493 
change in pH enables the auto-catalytic processes to activate PC2. This in turn 494 
causes the cleavage of the C-terminal 7B2 peptide which releases the PC2 (244). 495 
Thus, the biosynthesis and activation of PC2 is tightly linked with that of 7B2. 496 
 497 
When 7B2 is knocked out in mice (422), the activity of PC2 in the pars 498 
intermedia of the pituitary is prevented. The mice fail to produce -MSH and 499 
instead have dramatically increased ACTH levels and display a Cushing’s 500 
syndrome-like phenotype with central obesity. Mortality from the excess ACTH 501 
can be rescued by adrenalectomy (214). PC2 null mice have higher ACTH in the 502 
pars intermedia of the pituitary than 7B2 null mice, but the 7B2 null mice secrete 503 
more ACTH providing further evidence for the role of 7B2 in the regulated 504 
secretory process.  505 
 506 
4. Role of proSAAS in inhibition of PC1/3 507 
 508 
With the discovery of 7B2, there was a suggestion that endogenous inhibitors of 509 
PC1/3 might also exist. This led to the identification of proSAAS as a potential 510 
inhibitor of PC1/3. ProSAAS is expressed primarily in the brain and in other 511 
neuroendocrine tissues. Its overexpression in AtT20, mouse pituitary 512 
corticotroph adenoma cells, reduces POMC processing by inhibiting PC1/3, but 513 
PC2 is not affected (138).  514 
 515 
5. Cellular site of action of PC1/3 and PC2 516 
 517 
The subsequent identification of other members of this family of convertases, 518 
along with cellular localization studies has revealed that the majority of these 519 
endoproteases cleave peptides in the TGN or at the plasma membrane. In 520 
comparison, PC1/3 (238) and PC2 (238) cleave the peptides in dense core 521 
secretory granules (100). This is very relevant as their targets are primarily 522 
hormones and neuropeptides, like POMC, and the regulation of the release of the 523 
active peptides is critical for the function of these hormones. Although it has 524 
been suggested that PC1/3 does not have a transmembrane domain (238), the 525 
endogenous 84 kDa and 66 KDa forms of PC1/3 can associate with the secretory 526 
granule membranes in a lipid raft, with the N-terminal portion on the luminal 527 
side and the region 619-638 acting as a transmembrane domain. This leaves 528 
approximately 115 amino acids from the C-terminus of PC1/3 in the cytoplasm, 529 
although an -helical domain at the C-terminus may associate with the 530 
cytoplasmic side of the secretory granule membrane. Therefore, the catalytic 531 
domain would be within the lumen of the secretory vesicle and cleavage at 532 
Arg617-Arg618, adjacent to the membrane, would produce the mature PC1/3 (10). 533 
It has been suggested that the insertion into the membrane occurs in the rough 534 
ER cisternae and that PC1/3 is transported to the TGN in this form and 535 
subsequently packaged into secretory vesicles (10). Sorting PC1/3 and other 536 
enzymes to the regulated secretory pathway is an important mechanism and PC2 537 
and carboxypeptidase E (CPE) may also associate with lipid rafts. However, an 538 
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alternative suggestion for PC1/3 is that the pro-region associates with lipid rafts 539 
and this facilitates the sorting to the secretory pathway (35).                                                                                                                              540 
 541 
6. Tissue specificity of PC1/3 and PC2 in the processing of POMC 542 
 543 
Further confirmation of the function of PC1/3 and PC2 came from their tissue 544 
specificity in the mouse pituitary (352, 353), where PC1/3 and PC2 mRNA were 545 
detected in the pars intermedia, but only PC1/3 mRNA in the anterior lobe. 546 
There was some controversy as studies on the rat pituitary revealed a slightly 547 
more complex picture based on in-situ hybridization and co-localization (91). 548 
There were high levels of PC1/3 in the anterior pituitary but also lower but 549 
significant levels of PC2. However this was clarified when co-localization 550 
experiments indicated that the PC2 was not present in the cells that express 551 
POMC. In comparison the pars intermedia had much higher expression of PC2 552 
than PC1/3 (91).    553 
 554 
The presence of PC1/3 in the anterior pituitary enables the processing of POMC 555 
to ACTH, -LPH, N-POMC (148) and presumably joining peptide, although there 556 
are very few studies that have focussed on the molar ratios of each of the 557 
peptides. The lack of readily available assays for N-POMC and joining peptide 558 
makes it difficult to measure these peptides in human plasma and to predict if 559 
there is processing between N-POMC and joining peptide. The absence of PC2 560 
from the anterior pituitary means that further processing of the peptides does 561 
not occur. 562 
 563 
In comparison, the presence of PC2 in the hypothalamus and skin causes the 564 
further cleavage of ACTH, -LPH and N-POMC. This provides substrates for other 565 
enzymes to complete the processing to -MSH, -MSH and -MSH.  566 
 567 
PC2 is also found in the pars intermedia of the pituitary, which is present in 568 
rodents and the fetal human pituitary. This means that processing is more 569 
extensive and the melanocortin peptides are released under the control of 570 
regulatory mechanisms, which are distinct from those in the anterior pituitary. 571 
When POMC was co-expressed with PC1/3 and PC2, using vaccinia virus vectors 572 
in cells that exhibit regulated secretion, a very similar cleavage pattern of 573 
processing was observed to that seen in the pars intermedia of the pituitary (15, 574 
398). However, such studies have to be viewed with caution, because of potential 575 
degradation of the cellular environment by the virus, and because of some 576 
observed ambiguities in that glucagon was not processed from pro-glucagon by 577 
PC2 using a similar method.  578 
 579 
7. POMC converting enzyme (PCE or Yapsin A) 580 
 581 
Although many studies indicate that PC1/3 and PC2 are the major convertases, 582 
there are aspartyl-like proteases which may be involved in processing POMC in 583 
certain circumstances. A mammalian aspartyl protease was identified in 1985 584 
called POMC converting enzyme (PCE) (224). This is immunologically related to 585 
Yapsin 1, which processes at paired basic residues in Kex2 deficient cell lines. 586 
 587 
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PCE cleaves POMC to give 21-23kD ACTH, 4.5kD ACTH and 13kD ACTH 588 
(glycosylated), -LPH and -endorphin. It also cleaves -LPH to give -MSH 589 
(222). The gene for PCE has not been cloned, and therefore no in-situ analysis 590 
has been undertaken (50). 591 
 592 
B. Other processing enzymes involved in generating POMC-derived 593 
peptides 594 
 595 
The further processing of POMC after the action of PC1/3 and PC2 involves 596 
multiple stages and many different enzymes (Figure 1). The production of -, -, 597 
and -MSH is particularly complex and occurs in the pars intermedia of the 598 
pituitary (in rodents) and in other tissues such as the arcuate nucleus of the 599 
hypothalamus and the skin.  600 
 601 
1. Carboxypeptidase E 602 
 603 
As stated above, the pro-hormone convertases process peptides usually at the 604 
carboxyl residue after the single or paired basic amino acid motif. After cleavage, 605 
the Lys and/or Arg residues are removed by carboxypeptidase E (CPE) also 606 
known as carboxypeptidase H or encephalin convertase (reviewed in (50)). 607 
Therefore, in the human anterior pituitary, once POMC has been processed by 608 
PC1/3 at the C-terminal of ACTH there is a Lys-Arg pair of amino acids that are 609 
then removed by a carboxypeptidase.  610 
 611 
Similarly, in the production of -MSH, CPE plays an important role in removing 612 
Lys and/or Arg residues from the C-terminus of ACTH (1-17). Then there is 613 
further removal of glycine to generate the 13 amino acid peptide which is post-614 
translationally modified to generate -MSH. This is described in more detail in 615 
section 2 below.  616 
 617 
However there is more to the function of CPE than just its role in removal of 618 
basic amino acid residues and it may well be that its secondary role is the more 619 
important one for POMC processing. In 1997, Peng Loh’s group showed that CPE 620 
also acts as a pro-hormone sorting receptor for the regulated secretory pathway 621 
(83). This function is necessary for pro-hormones to move from the TGN into 622 
secretory granules (see below). The importance of this role is indicated by the 623 
results from the Cpe gene deletion which highlights the miss-sorting of pro-624 
hormones (83, 357). 625 
 626 
2. Peptidylglycine -Amidating Monooxygenase (PAM)  627 
 628 
Peptidylglycine -Amidating Monooxygenase (PAM) amidates the C-terminal of 629 
ACTH (1-13) in the pathway creating -MSH but it can also amidate the C-630 
terminal of joining peptide (reviewed in (210)). This process occurs when the 631 
POMC-derived peptides are in the secretory granules. It is difficult to find any 632 
evidence for a role for ACTH (1-13) without the subsequent modifications so this 633 
suggests PAM is critical in the generation of -MSH. 634 
 635 
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As the name implies, PAM amidates the C-terminal of peptides after the basic 636 
amino acid residue has been cleaved by CPE, and primarily at glycine extended 637 
peptides such as is found in the processing to -MSH. PAM is found in most large 638 
dense core secretory vesicles (120) and exists as a bifunctional enzyme with a 639 
peptidylglycine -hydroxylating monooxygenase (PHM) domain which catalyses 640 
the first stage in the process and a peptidyl--hydroxyglycine -amidating lyase 641 
(PAL) domain which catalyses the second stage. The PAL domain is attached to a 642 
transmembrane domain and a cytosolic domain so both catalytic units are held 643 
at the membrane but project into the lumen of the large dense core secretory 644 
vesicles (68). Secretory granule endoproteases cleave the two domains from the 645 
membrane so that they exist in the lumen of the granules. However there is also 646 
a naturally occurring soluble form called PHM4, made up of only the PAL domain 647 
and generated by alternative splicing (68). There is also evidence that PAM alters 648 
the organization of the actin cytoskeleton which is important in the release of 649 
secretory vesicles from cells (121). 650 
 651 
The role of PAM in POMC processing in the hypothalamus has received little 652 
attention and there are currently no reports of mutations in humans that have 653 
resulted in obesity. If PAM is critical in the generation of -MSH, in subjects 654 
carrying deleterious inactivating mutations, it may be there is a degree of 655 
redundancy in the system with other enzymes undertaking similar amidating 656 
activity to compensate. 657 
 658 
3. N-acetyl transferase 659 
 660 
Acetylation of the N-terminal amino acid residues of -MSH and -endorphin is 661 
important for the activity of these peptides. In general it is a process thought to 662 
protect peptides from aminopeptidases and therefore increase their stability 663 
although some peptides have N-terminal acetylation which targets them for 664 
degradation. N-terminal acetylation is generally restricted to intracellular 665 
proteins (429). Therefore the N-acetylation of these two peptides, whose role is 666 
to act at distant sites within the brain and the skin, remains intriguing and not 667 
fully explained.  668 
 669 
A) ACETYLATION IN DIFFERENT TISSUES 670 
The deacetylated form of -MSH was identified in the pituitaries of a number of 671 
species as early as 1974 (see (273)), but studies in the 1980s suggested that 672 
most of the -MSH is in the acetylated form in the pars intermedia the pituitary 673 
(97).  674 
 675 
In the human and rat hypothalamus, deacetylated -MSH (subsequently termed 676 
des-acetyl -MSH) was found to be a major component when assessed with 677 
HPLC techniques (273). Subsequently the regional heterogeneity in the forms of 678 
-MSH was investigated. In the arcuate nucleus of the hypothalamus, where this 679 
peptide has a major role, there was some -MSH, but the majority was in the des-680 
acetyl form. The amygdala and periaqueductal grey contained non-acetylated -681 
MSH and the nucleus accumbens had the mono- and di-acetyl (second acetyl 682 
group on the third amino acid) forms of -MSH (97). In a separate study which 683 
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showed the prevalence of des-acetyl -MSH in the arcuate nucleus, it was also 684 
suggested that acetylation occurred in the NTS because -MSH was found there 685 
(113).  686 
 687 
B) WHAT DOES N-TERMINAL ACETYLATION DO FOR -MSH? 688 
In in vitro studies, the potencies of des-acetyl -MSH and -MSH appear similar 689 
at MC3R and MC4R (Abbott ref 1 in this review). There is however some 690 
evidence that the two forms of -MSH may activate intracellular signaling 691 
pathways differently and this could vary depending on the type of tissues and the 692 
different melanocortin receptors (429).  693 
 694 
That there is a difference in biological function between des-acetyl -MSH and -695 
MSH has been recognized for some time in terms of behavioural effects (273). 696 
However, there are also several in vivo studies showing differences in the 697 
potencies of the N-acetylated and the des-acetyl forms of -MSH, in terms of food 698 
intake (reviewed in (258, 429)). These studies indicated that when des-acetyl 699 
and -MSH are injected icv at the same dose, des-acetyl -MSH had a much 700 
smaller effect on food intake (1, 261, 404). However a recent study in mice 701 
lacking endogenous -MSH and des-acetyl -MSH, demonstrated that when 702 
these peptides were administered they could each equally decrease body weight 703 
(259) presumably by reducing food intake.  704 
 705 
What may be most relevant is that the N-terminal acetylation of -MSH confers 706 
stability on the peptide (47, 156, 272, 336). Des-acetyl -MSH is readily 707 
degraded by aminopeptidases where-as the N-terminal acetylation protects -708 
MSH from such degradation (156). Therefore, acetylation could be a mechanism 709 
by which the biological activities of POMC peptides are modulated, although 710 
further work needs to be carried out to fully understand the endogenous effects 711 
of the peptides. 712 
 713 
There is also evidence that leptin induces an N-acetylase in mouse hypothalamus 714 
(156), so in addition to increasing the POMC gene expression, it was suggested 715 
that leptin could increase the biologically active -MSH in relation to the less 716 
active des-acetyl -MSH form. This suggests much greater subtlety in the control 717 
of POMC processing to melanocortin peptides. Some explanation is required, 718 
because the evidence points to very little of the active N-acetylated -MSH 719 
relative to des-acetylated -MSH in the arcuate nucleus (113), making it difficult 720 
to understand how -MSH can have such a powerful role in regulating energy 721 
balance. There is speculation that the acetylation process occurs after the des-722 
acetyl -MSH has travelled along the neuron and just before secretion of the 723 
vesicles (258) in the paraventricular nucleus of the hypothalamus (PVN) (Figure 724 
3). Therefore the relative concentrations of -MSH and des-acetyl -MSH in the 725 
arcuate nucleus would be less relevant. 726 
 727 
To add to the complexity, there is evidence that -MSH is processed by 728 
prolylcarboxypeptidase (PRCP) to give -MSH (1-12), which is inactive. (see 729 
section 4 below for more details). 730 
 731 
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Figure 3: POMC processing in neurons 732 
 733 
 734 
C) ACETYLATION OF -ENDORPHIN 735 
Non-acetylated -endorphin is found in the arcuate nucleus of the hypothalamus 736 
but acetylated -endorphin was thought to be the main form in the NTS (113). 737 
This again raises issues about the role of these post-translational modifications 738 
as acetylated endorphins do not bind to opiate receptors (3) and therefore the 739 
process of acetylation prevents opiate activity (92). However a more recent 740 
study has demonstrated opioid activity originating from POMC neurons in the 741 
NTS, indicating that non-acetylated -endorphin may also be released from these 742 
neurons (54). 743 
 744 
D) RATIONALIZATION OF ACETYLATION FUNCTION 745 
There is evidence to suggest that the acetylation of -MSH and -endorphin is 746 
tissue specific and differs between the hypothalamus and pituitary (258). The 747 
presence of N-acetyltransferase in the processing cascade would increase -748 
MSH, thus potentiating -MSH activity and acetylate -endorphin thus reducing 749 
its function.  Therefore this could be a mechanism to provide distinct 750 
melanotropic action and not opiate effects in the specific brain region.  751 
 752 
4. Prolylcarboxypeptidase (PRCP) 753 
 754 
A further cleavage of -MSH can be carried out by prolylcarboxypeptidase 755 
(PRCP) giving -MSH (1-12), which has been demonstrated to occur both in 756 
vitro, and in vivo (417). Additionally, there is evidence that prolyl endopeptidase 757 
(PREP, also known as prolyl oligopeptidase) can cleave the terminal amidated 758 
valine of -MSH to also give -MSH (1-12) (304). The function of -MSH (1-12) 759 
is unclear as it does not activate MC4R and does not decrease food intake (417) 760 
and is therefore assumed to be inactive. 761 
 762 
 763 
IV.  THE CELLULAR PATHWAY TO SECRETION  764 
 765 
Another critical arena that determines how POMC derived peptides are released 766 
from cells in the correct spatial and temporal patterns is the pathway across the 767 
component parts of the intracellular secretory pathway. It is important to note 768 
that much of the work in this area has been carried out in the mouse pituitary 769 
adenoma (AtT20) cell line. It remains to be determined how this secretory 770 
pathway may differ from that in hypothalamic neurons where there are long 771 
projections between regional nuclei. Nevertheless, there are much data which 772 
suggest POMC peptides follow at least 2 distinct pathways on their journey from 773 
translation to the extracellular space. 774 
 775 
A. From the Endoplasmic Reticulum (ER) to the trans-Golgi Network 776 
(TGN)  777 
 778 
After translation, all pro-hormones are moved into the ER where the N-terminal 779 
recognition signal anchors them to the membrane. The ER then plays a role in 780 
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removing the signal peptide at the N-terminal of POMC using a signalase enzyme 781 
(119). POMC has a specific “heart shaped” conformation at its N-terminal which 782 
occurs by the formation of two disulphide bonds formed from Cys28/Cys50 and 783 
Cys34/Cys46 in the region upstream of -MSH, sometimes termed the 16K 784 
fragment (19, 80). As POMC passes out of the ER it will have had N-linked 785 
oligosaccharides added, which can influence processing or have no effect, 786 
depending on the region that is glycosylated (17). 787 
 788 
B. From the Golgi to the secretory vesicle 789 
 790 
In the Golgi apparatus the pro-hormone is moved towards the ends of the 791 
cisternae where there is blebbing of the membranes to generate the secretory 792 
vesicles (399). During this process, the serine at amino acid 31 in ACTH is 793 
phosphorylated by casein kinase and sulphate groups are added to N-linked 794 
carbohydrate chains.  795 
 796 
The sorting of pro-hormones for processing is dependent on a change in pH 797 
between the TGN and the secretory granules. Experiments using chloroquine, 798 
which neutralises acidic compartments, resulted in a reduction of newly 799 
synthesized ACTH in mature granules (256). As POMC moves through the TGN 800 
and into granules, the pH changes from 6.8 (355) to 4.5-5.5 (225) which is 801 
coupled with changes in calcium concentrations. This environment provides the 802 
optimal conditions for activation of the pro-hormone convertases, so that the 803 
initial phases of processing of the pro-hormone precursor can begin. There is 804 
data suggesting that POMC is primarily processed in secretory granules (134, 805 
394) although other studies suggest it may begin in the TGN (249, 345, 445). 806 
Some of the evidence suggests that the initial cleavage of POMC at the C-terminal 807 
of ACTH can occur in the Golgi apparatus but subsequent modifications continue 808 
in the secretory vesicles (reviewed in (313)). Therefore the cleavage at the N-809 
terminal of ACTH to generate mature ACTH (1-39) is likely to occur in the 810 
secretory vesicles (Figure 4). 811 
 812 
Figure 4: Alternative secretory pathways for precursors and POMC-derived 813 
peptides 814 
 815 
If the initial cleavage between ACTH and -LPH occurs in the Golgi apparatus, 816 
then it is likely that -LPH (and therefore -endorphin) could be found in 817 
different vesicles to ACTH and -MSH. If all the processing occurs in the vesicle, 818 
then ACTH and -endorphin will be present in the same vesicles. This is 819 
important for understanding whether -MSH and -endorphin peptides are 820 
released at the same time and at the same site, given that they may have 821 
opposing roles in the hypothalamus (See section on -endorphin in the 822 
hypothalamus).  823 
 824 
Further processing of ACTH to -MSH requires not only PC2 but also the 825 
enzymes CPE, PAM, and N-AT (see above) which are present in the secretory 826 
vesicles in a state ready to be activated. How activation is achieved is not fully 827 
understood (100). It is likely that these enzymes have recognition sequences that 828 
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direct them to the TGN, but whether all secretory vesicles have this repertoire of 829 
enzymes is not clear.  830 
 831 
C. What is the regulated secretory pathway?  832 
 833 
Gumbiner and Kelly in 1982 recognized that there are classical secretory cells 834 
such as those in the adrenal medulla, the exocrine pancreas and the anterior 835 
pituitary which have large dense core secretory granules (155). They defined the 836 
regulated secretory pathway (RSP) as one where secretagogues controlled the 837 
release of the contents of the secretory vesicles. In the absence of secretagogues 838 
there is minimal exocytosis of secretory granule contents. The secretory vesicles 839 
have an electron dense core and turn over is slow (half life approximately 10 840 
hours), probably because these are the storage organelles for bioactive peptides. 841 
Biogenesis of secretory granules was initially thought to require chromogranin A 842 
(CGA), a member of the granin family which also includes chromogranin B (CGB, 843 
secretogranin I) and chromogranin C (CGC, secretogranin II) (199). However 844 
targeted ablation of the chromogranin A (Chga) gene indicates that 845 
compensatory increases in the expression of other granin family members can 846 
compensate for CGA deficiency (163).   847 
 848 
D. Pro-hormone sorting 849 
 850 
Sorting of peptides to the regulated secretory pathway (RSP) is a pre-requisite 851 
for processing of many pro-hormones. Although not fully clarified, it is 852 
reasonable to assume that this is also the case for pro-neuropeptides involved in 853 
energy balance. These are released from neurons that have their cell bodies in 854 
the arcuate nucleus but act at other sites within the hypothalamus. POMC 855 
neurons will release -MSH primarily at the PVN. The molecular mechanisms for 856 
sorting pro-hormones to the RSP can involve aggregation of peptides in the 857 
presence of high calcium and low pH, as found in the TGN. There is evidence for 858 
aggregation of this type for chromogranins A and B (59) however, sorting can 859 
occur in the absence of aggregation (316) and other studies have suggested the 860 
importance of sorting signal motifs. 861 
 862 
POMC has a sorting signal motif at its N-terminal region that is both necessary 863 
and sufficient for sorting to the RSP (80-82). This sorting signal in POMC was 864 
identified as a result of some of the early structural analysis of the N-terminus of 865 
POMC (18, 19). It is thought to involve two acidic residues, Asp10 and Glu14, and 866 
two amphipathic residues, Leu11 and Leu18, which are part of an amphipathic 867 
loop at POMC residues 8-20. This sequence was predicted to be a consensus 868 
sorting signal which could bind to a sorting receptor and it has also been 869 
identified in pro-enkephalin (270) and pro-insulin (99). 870 
 871 
For POMC, the sorting receptor was identified as carboxypeptidase E (CPE) (81, 872 
83). This has a ligand binding domain for the POMC sorting motif, which was 873 
originally identified by molecular modeling and then disruption of the receptor 874 
site by mutation (441). The binding site on CPE, which is distinct from the 875 
enzyme active site, also recognizes pro-insulin and pro-enkephalin (441). CPE is 876 
known to associate with membranes and this appears to be necessary for its 877 
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function in sorting pro-hormones to the RSP (98). This membrane association is 878 
with lipid rafts containing glycosphingolipids and cholesterol and is 879 
predominantly in the secretory granules, but also in the TGN. Depletion of 880 
cholesterol can reduce the association of CPE and its pro-hormone ligand with 881 
the membrane (98). Secretogranin III can also have a synergistic role with CPE in 882 
the trafficking of POMC and derived peptides (50). RNA silencing of 883 
secretogranin III decreases secretion through the RSP in AtT20 cells suggesting 884 
that there are several pathways involved in regulated secretion (51).  885 
 886 
Much of the work on the membrane association of CPE has used secretory 887 
granules and it is not clear at what stage CPE binds to POMC. For CPE to be 888 
involved in sorting POMC from the ER to the TGN it would have to bind in the ER 889 
in order to transfer it into compartments within the TGN. However, as POMC 890 
moves through the TGN, CPE can enable POMC to be selected for immature 891 
granules that bud off the TGN. The interaction between CPE and POMC would 892 
then retain POMC in the granules and not allow it to move to the constitutive-like 893 
pathway (see below). 894 
 895 
The relative importance of the roles of CPE in sorting of POMC to the RSP versus 896 
its true carboxypeptidase action has not been clearly delineated. Sorting seems 897 
to be critical because POMC is not processed but secreted in large amounts from 898 
the constitutive pathway in the pituitary of the Cpefat/fat mice (83, 357). 899 
 900 
Another carboxypeptidase, CPD, is present in the TGN and cycles between the 901 
TGN and the cell surface. It appears to reside in immature secretory granules, but 902 
absent from the mature granules (411). Therefore CPD may be responsible for 903 
removal of dibasic amino acids or sorting of pro-hormones in the absence of CPE 904 
(102).  905 
 906 
E.  The movement of vesicles to the cell membrane 907 
 908 
For POMC, one of the critical features is the very specific regulation of release of 909 
the processed peptides in response to defined signals. The cytoplasmic tail of 910 
CPE (i.e. the part of the molecule that remains outside the vesicle) also plays a 911 
role in transporting the vesicles containing POMC (or if POMC has been 912 
processed then the vesicles which contain ACTH and the other POMC-derived 913 
peptides). The secretory vesicles must be transported from the TGN to the cell 914 
membrane where they can be stored until there is a stimulus which orchestrates 915 
their release. The transport of the vesicles to the secretion sites in pituitary cells 916 
occurs along microtubules (205). This involves dynactin being recruited to the 917 
cytoplasmic tail of CPE, and dynactin then binding to kinesin 2 and kinesin 3 as 918 
part of the secretory process (50, 295). The very specific mechanisms involved in 919 
movement of vesicles to the cell membrane have been reviewed by Park and Loh 920 
(295). 921 
 922 
F.  What happens to the mature peptides in the secretory vesicles? 923 
 924 
The current working model is one in which the processing of POMC to the 925 
smaller peptides continues during the time when the vesicles are trafficking to 926 
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the site of secretion. There is evidence that within dense core secretory vesicles a 927 
large number of peptide and protein hormones aggregate into insoluble 928 
macromolecular complexes (237). These aggregates are crystalline or composed 929 
of amyloid fibrils which are cross--sheet structures. Interestingly, ACTH was 930 
one of the hormones that didn’t form amyloid-like aggregates on its own, but 931 
when mixed in vitro with -endorphin, in the presence of heparin, the amyloid 932 
fibrils were formed. There is the caveat that -endorphin does not seem to be 933 
processed from -LPH in human pituitary cells so it is not clear if ACTH would 934 
form amyloid fibrils in this instance. Nevertheless, there is also evidence for 935 
amyloid aggregates in the mouse pituitary cell line AtT20, which is known to 936 
secrete ACTH and presumably -LPH (237).  937 
 938 
There is a suggestion that pro-hormones aggregate less than the hormones 939 
derived from them (438). Therefore processing of the pro-hormone may be 940 
necessary before amyloid aggregation occurs. This would sort the hormone into 941 
the granule core and concentrate the molecules, excluding those hormones that 942 
don’t aggregate which are then constitutively secreted (237). It is thought that 943 
the amyloid aggregation begins in the Golgi where the membrane surrounds the 944 
aggregates, although for POMC and ACTH this will depend on the degree of 945 
processing. The amyloid aggregates are stable and therefore they can be stored, 946 
but on stimulation there is a change in pH which is thought to trigger the 947 
dissociation of the monomeric hormone from the amyloid allowing its release 948 
from the cell (237). Whether this occurs in vivo and how it contributes to 949 
efficient processing is harder to determine. 950 
 951 
G. Release of secretory vesicles from the cell  952 
 953 
Once the anterior pituitary cell is stimulated to release ACTH, the vesicles have to 954 
dock with the cell membrane. VAMP2, syntaxin 1 and SNAP-25 form a core 955 
complex (380) that interacts with NSF and SNAPs. These are termed SNARE 956 
proteins and together with synaptotagmin 1 are responsible for synaptic vesicle 957 
priming, docking and fusion to the cell membrane. Each of the core complex 958 
proteins is related to other similar proteins in their class, which could give rise to 959 
specific combinations of these proteins in different complexes (20, 390). For the 960 
secretory vesicles to fuse with the plasma membrane, a complex process occurs 961 
involving actin and tubulin (399). This enables the secretory vesicles to exude 962 
their products into the extra-cellular space. 963 
 964 
Exocytosis is coupled to specific extracellular stimuli, such as CRH binding to its 965 
receptors on anterior pituitary cells and signaling to evoke secretion (111). How 966 
the receptor activation signals to the machinery for release of the secretory 967 
vesicles is very relevant, as the whole procedure must occur in milliseconds to 968 
release ACTH in times of stress. The release of ACTH from pituitary cells is also 969 
stimulated by arginine vasopressin (AVP) and inhibited by glucocorticoids and 970 
this process has to synchronise with the mechanisms of release of the secretory 971 
vesicles. More details of the regulation of secretion of ACTH are found in Section 972 
IV. 973 
 974 
 975 
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H. Constitutive versus regulated secretion  976 
 977 
In addition to the regulated secretory pathway, there is also a constitutive 978 
pathway of secretion, which is a route allowing the release of peptides from cells 979 
which is not regulated by external factors (155); examples of peptides released 980 
in this way include lysosomal enzymes secreted by fibroblasts (166), and 981 
acetylcholinesterase released from muscle cells (332). This pathway can be 982 
inhibited by monensin which is an ionophore that can inhibit the transport of 983 
secretory proteins through the TGN. 984 
 985 
For secretory cells, there is evidence to suggest they have both constitutive and 986 
regulated secretory pathways. Moore et al. stably transfected pro-insulin into 987 
AtT20 cells, which synthesise and process POMC to ACTH and therefore should 988 
have all the secretory components (257). They showed that AtT20 cells rapidly 989 
release newly synthesized pro-insulin from a constitutive pathway and store the 990 
processed insulin for release after stimulation by a secretagogue. There is 991 
evidence that the constitutive pathway releases peptides over about 40 minutes 992 
(155). If the regulated pathway is blocked by chloroquine, then newly 993 
synthesized ACTH is released from the constitutive pathway, which is further 994 
evidence that both pathways exist in secretory cells. 995 
 996 
There are two mechanisms proposed for targeting peptides to vesicles. If the 997 
targeting occurs in the TGN then it is termed “sorting by entry” (279, 400), but if 998 
it occurs in the immature secretory granules (ISGs) then it is termed “sorting by 999 
retention” (209). There is evidence for both mechanisms and despite much effort 1000 
to unravel the processes that target peptides to granules there are still many 1001 
unanswered questions (100).  1002 
 1003 
I. Release of POMC from the constitutive-like pathway 1004 
 1005 
There is some early evidence to suggest that POMC is released from the 1006 
constitutive pathway (256) (Figure 4). Analysis of how POMC is processed and 1007 
how it is trafficked into secretory or constitutive granules utilized radiolabelling 1008 
of the sulphates on carbohydrate chains linked to POMC in the TGN. POMC 1009 
processing to convert POMC to ACTH began in the ISGs. However, incompletely 1010 
processed POMC was also secreted in ISGs by a distinct pathway which has been 1011 
termed the constitutive-like pathway (110).  1012 
 1013 
With the advent of a specific and sensitive two-site immunoassay for POMC (89), 1014 
it has become possible to compare direct measurement of POMC and ACTH 1015 
release from AtT20 cells. When cells are cultured under basal conditions then 1016 
much higher concentrations of POMC than ACTH are released. After stimulation 1017 
with corticotropin releasing hormone (CRH) for 2 hours there is a 2-fold increase 1018 
in secreted ACTH with no change in secretion of ACTH precursors (384), 1019 
suggesting ACTH is released from the regulated pathway but POMC is released 1020 
from the constitutive-like pathway.  1021 
 1022 
However there are a number of caveats, the first being that the AtT20 cells 1023 
release extremely high concentrations of ACTH-related peptides compared with 1024 
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normal mouse corticotrophs. Therefore, their secretory capacity may be 1025 
different and the regulatory mechanisms may not reflect “normal” cells. A second 1026 
caveat is that all ACTH assays recognize ACTH precursors to some degree (255), 1027 
so the “ACTH” measured may in fact be ACTH precursors. We have calculated 1028 
that ACTH precursors have <10% cross-reactivity in the ACTH assay we have 1029 
developed (385). Therefore the concentrations of precursors are contributing 1030 
only a small amount to the ACTH concentrations measured. 1031 
 1032 
 1033 
V.  RECEPTORS BINDING POMC-DERIVED PEPTIDES 1034 
 1035 
The processed products of POMC bring about their biological actions through 1036 
melanocortin receptors (MCRs) and the µ-opioid receptor. These will be briefly 1037 
discussed below, but are reviewed in detail in Cone et al. (77) and Pasternak and 1038 
Pan (298).  1039 
 1040 
A. Melanocortin Receptors 1041 
 1042 
The five melanocortin receptors (MC1R-MC5R), are differentiated by their tissue 1043 
localization and ligand affinity (Table 1). They were named in the order they 1044 
were discovered, rather than any association with their localization or ligands.  1045 
 1046 
1. Melanocortin 1 Receptor (MC1R) 1047 
 1048 
MC1R is located primarily in melanocytes of skin and in hair follicles, but is also 1049 
expressed in macrophages and adipocytes (169). The main role of melanocortin 1050 
signaling through MC1R is in regulation of pigmentation in the skin and in hair 1051 
follicles. Activation of MC1R by its ligand causes a switch from synthesis of the 1052 
red and yellow, pheomelanin pigments,  to the black and brown, eumelanin 1053 
pigments. Mutations and variants of the MC1R have been found in patients with 1054 
red hair and fair skin (409). There is also evidence that activation of MC1R can 1055 
promote cell proliferation, DNA repair and cell survival. 1056 
 1057 
The primary ligand of MC1R is -MSH, which is endogenously produced in the 1058 
keratinocytes of skin and hair after exposure to UV light. Additionally, ACTH is 1059 
also able to activate MC1R and at high concentrations (such as when secreted 1060 
from tumors) it can cause hyperpigmentation (406). There is also some evidence 1061 
that MC1R can bind -MSH and γ-MSH with lower affinity. 1062 
 1063 
2. Melanocortin 2 receptor  (MC2R) 1064 
 1065 
The MC2R is also known as the ACTH receptor. It is unique among the MCR 1066 
family as it only binds ACTH and is unable to bind any of the MSH peptides. The 1067 
MC2R also has a much lower sequence homology with other melanocortin 1068 
receptors and in particular, it only has 38% homology with MC4R. This is 1069 
primarily because MC2R has a different binding pocket compared to the other 1070 
MCRs (436). MC2R is predominantly expressed in the adrenal cortex and 1071 
requires the accessory protein, MRAP, to enable it to translocate to the cell 1072 
surface so it can function. Binding of ACTH to the MC2R activates the cascade for 1073 
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synthesis of glucocorticoids as part of the HPA axis. 1074 
 1075 
3. Melanocortin 3 receptor (MC3R) 1076 
 1077 
The MC3R has a more minor role in energy homeostasis compared to MC4R, and 1078 
acts primarily as an inhibitory “auto-receptor” on POMC neurons in the arcuate 1079 
nucleus, the region associated with energy balance. It binds -, - and γ-MSH and 1080 
ACTH, equipotently (144). The MC3R is expressed in the hypothalamic region of 1081 
the brain, but also in the limbic regions (331) and in peripheral tissues including 1082 
the stomach, duodenum, pancreas, heart, testis, ovary, skeletal muscle and 1083 
kidney (78). However the role of MC3R in these tissues is not as well defined. 1084 
 1085 
4. Melanocortin 4 receptor (MC4R) 1086 
 1087 
Many studies have elucidated the role of the MC4R in regulation of food intake 1088 
and energy expenditure. MC4R is widely expressed throughout the CNS, but has 1089 
a very high expression level in the PVN of the hypothalamus (260). Historically, 1090 
the primary agonist for MC4R has been considered to be -MSH, although as 1091 
discussed in this review, and reviewed elsewhere (311), other POMC derived 1092 
peptide agonists such as des-acetyl -MSH and -MSH are likely to have similar 1093 
physiological relevence. The primary agonist for MC4R is -MSH, which is 1094 
released from POMC neurons in the PVN. The antagonist for MC4R, AgRP, is also 1095 
released in the PVN, from the orexigenic AgRP/NPY neurons. The release of both 1096 
the agonist and the antagonist at the receptor allows for a complex regulatory 1097 
mechanism for signaling via MC4R in the PVN.   1098 
 1099 
5. Melanocortin 5 receptor (MC5R) 1100 
The function of the MC5R is not as well understood as the other MCRs. It is highly 1101 
expressed during embryogenesis and is known to be involved in exocrine gland 1102 
function. Its expression pattern is different to the other MCRs in that it is widely 1103 
expressed in a large variety of peripheral tissues, however it is not expressed in 1104 
the CNS (78). The primary ligand at MC5R is -MSH, but ACTH, -MSH and γ-1105 
MSH are also able to bind. 1106 
 1107 
B.  µ-Opioid Receptors 1108 
 1109 
Clearly, -endorphin is different to other POMC-derived peptides in that it does 1110 
not have the MSH sequence and therefore does not signal through a 1111 
melanocortin receptor, but instead binds to the µ-opioid receptor. Although -1112 
endorphin is the only POMC-derived peptide said to bind this type of receptor, it 1113 
is not clear whether its immediate precursor, -lipotropin, might also bind the 1114 
receptor. It is thought that in adult humans, POMC is primarily processed to -1115 
lipotropin and so -endorphin, would not be released from the pituitary to act on 1116 
peripheral tissues. There is also the complexity as to how well other endorphins 1117 
bind the receptors and the implications for morphine as a substrate.  1118 
 1119 
µ-opioid receptors are expressed centrally in regions including the cortex, 1120 
hippocampus, hypothalamus, and brain stem (292, 293, 301) and are widely 1121 
expressed in peripherally tissues including pancreas (421), testis (126, 432), 1122 
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Ovary (432) and kidney (432). These receptors not only mediate analgesic 1123 
effects, but can also play a role in the regulation of feeding behavior (as 1124 
described below). 1125 
 1126 
 1127 
VI.  ROLES OF THE COMPONENT PEPTIDES OF POMC  1128 
 1129 
In trying to understand the importance of POMC as the precursor to a number of 1130 
peptides, the inevitable question arises of why there are several bioactive 1131 
peptides in one precursor molecule (Figure 5). Is there a survival advantage to 1132 
having a single mechanism regulating the production of several peptides with 1133 
different functions? Is it just serendipity that several bioactive peptides are 1134 
present in the one precursor? If it is serendipitous evolution, then there are very 1135 
complex events to provide ACTH for its role in the HPA axis and a very different 1136 
set of mechanisms to generate -MSH as the key peptide in the melanocortin 1137 
regulation of energy balance. Alternatively, it may be that researchers working in 1138 
different fields have focused on specific aspects and not put as much emphasis 1139 
into investigating how other parts of the precursor may be involved. 1140 
 1141 
For researchers concentrating on the actions of -MSH in regulation of food 1142 
intake, it may not occur to them to question how POMC is processed to -MSH 1143 
and whether any of the other POMC-derived peptides could be contributing to 1144 
the effect. For example, POMC is processed to ACTH and then to -MSH, but 1145 
processing may not be totally efficient in the hypothalamus and if some ACTH is 1146 
present it could be acting at the MC4R. POMC itself has the amino acid sequence 1147 
of -MSH and could act at the MC4R, although because it is obviously a precursor 1148 
molecule, we tend to think of it being efficiently processed and therefore not 1149 
present outside the cell to act at receptors. However POMC is found in relatively 1150 
high concentrations in human CSF (286, 403) as well as in rat CSF (312), while -1151 
MSH is at least 10-fold lower than POMC and two fold lower than ACTH in rat 1152 
CSF. The much lower concentrations of -MSH are most likely due to rapid 1153 
degradation. Interestingly in hypothalamic extracts, -MSH is the most abundant 1154 
of the three POMC peptides and yet its concentrations does not differ between 1155 
lean and obese rats, while both POMC and ACTH are decreased in hypothalamic 1156 
extracts in obese animals (312). There is no doubt that it is much harder to 1157 
measure the different POMC peptides than it is to assess Pomc mRNA. The assays 1158 
for the different peptides require slightly different extraction procedures 1159 
especially when extracting them from hypothalamic tissue. These procedures 1160 
can also affect the subsequent immunoassay and careful optimization is required 1161 
to ensure the molar ratios are not affected by these processes.  1162 
 1163 
Given that these precursors are present, is it the relative affinity at the MC4R that 1164 
makes -MSH the only relevant ligand? However -MSH and ACTH have similar 1165 
binding affinities at this receptor (311), although POMC is thought to have a 1166 
lower affinity (White, unpublished data). Therefore, in understanding the 1167 
dynamic roles of the different peptides, we need to address the relative 1168 
importance of the processing pathway and the functionality of the different 1169 
peptides. 1170 
 1171 
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A. The Role of ACTH  1172 
 1173 
1. ACTH as an integral part of the HPA axis  1174 
 1175 
The central role of ACTH in the HPA axis is undisputed. Clearly the major 1176 
function of ACTH in stressful situations is to increase the concentration of 1177 
glucocorticoids in the blood, enabling them to have their pleiotropic actions. We 1178 
think of stress being evoked by trauma and pain, but other stressors such as 1179 
hemorrhage, infection, cold, hypoglycemia, inflammatory reactions, fear, 1180 
emotional events and exceptional exercise can all stimulate the HPA axis 1181 
response. 1182 
  1183 
When the HPA axis is stimulated, ACTH is released from the anterior pituitary 1184 
within minutes, to travel to the adrenal gland and increase glucocorticoids. The 1185 
most compelling evidence for the rapidity of the release of ACTH in humans, is 1186 
where patients are investigated for a pituitary tumor by petrosal sinus sampling. 1187 
In this investigation, patients are given CRH (peripherally) and the resulting 1188 
increase in ACTH in the petrosal sinuses draining the pituitary occurs within two 1189 
to three minutes (277). Therefore, this process must be stimulating release of 1190 
preformed ACTH and this ACTH must be in secretory vesicles, having been 1191 
processed from POMC and then stored in readiness to respond to stressful 1192 
stimuli. 1193 
 1194 
ACTH travels in the circulation and acts on the adrenal gland to cause the release 1195 
of cortisol in humans and corticosterone in rodents. This occurs in the zona 1196 
fasciculata where ACTH binds to the MC2R. The acute effect of ACTH in the stress 1197 
response occurs in the mitochondrion, where ACTH stimulates transcription and 1198 
translation of steroidogenic acute regulatory (StAR) protein, which in turn 1199 
increases translocation of cholesterol from the outer to the inner mitochondrial 1200 
membrane (14, 388). Cholesterol is then converted to pregnenolone by the 1201 
enzyme P450scc and the enzymatic cascade results in cortisol or corticosterone 1202 
(162, 250). This must occur very rapidly in situations where stress stimulates 1203 
the HPA axis.  1204 
 1205 
After an initial stressor, there may be a need to respond to another stress in a 1206 
relatively short timeframe. It has been suggested that one of the reasons for 1207 
having a precursor molecule is that it can be synthesized and stored in immature 1208 
secretory granules. Therefore if there is a repeated stressor, it is possible to 1209 
cleave POMC to ACTH quickly and release the bioactive molecule to provoke the 1210 
stress response, without the need for stimulation of the POMC gene. 1211 
 1212 
There is also a “basal” secretion of ACTH from the pituitary which has a diurnal 1213 
rhythm and this in turn evokes a circadian rhythm in cortisol. However there is 1214 
also a peripheral adrenal clock which modulates the diurnal rhythm of 1215 
steroidogenesis, leading to the diurnal differences in cortisol release. Thus the 1216 
basal ACTH secretion has an indirect role in modulating circadian biology, most 1217 
obviously through initiating the cortisol rhythms (67). 1218 
 1219 
 1220 
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2. Effects of ACTH on Adrenal Growth  1221 
 1222 
The “non-stress” effects of ACTH on the adrenal gland include a role in increasing 1223 
adrenal growth. This is somewhat controversial in that there are reports that this 1224 
role is performed by a peptide from the N-terminal region of POMC (N-POMC 1-1225 
28) (see below). However ACTH has a role in adrenal cortical development (187, 1226 
197) and ACTH replacement in POMC knockout mice is sufficient to cause 1227 
normal adrenal development (75).  1228 
 1229 
3. Role of ACTH in the skin 1230 
 1231 
There are well-recognized extra-adrenal effects of ACTH in the skin. These are 1232 
evidenced in some patients with excess secretion of ACTH-related peptides, e.g. 1233 
Addison’s disease and some ACTH secreting tumors, where there is marked 1234 
excess skin pigmentation, which decreases when ACTH levels are returned to 1235 
normal (426). This role of ACTH is described below in Section IX.  1236 
 1237 
4. Role of ACTH in adipocytes  1238 
 1239 
Work in the 1970s suggested that ACTH had lipolytic activity in rat and rabbit 1240 
adipocytes (320) and the effects of ACTH and MSH peptides on adipocytes have 1241 
been reviewed by Boston (39). In addition to effects on lipolytic activity, ACTH 1242 
and  -induced glucose 1243 
uptake, albeit mainly in murine 3T3-L1 cells (reviewed in (143)). Given that -1244 
MSH is not produced by the human anterior pituitary, the relevance of a role for 1245 
circulating -MSH in humans is difficult to interpret. However MC2R is 1246 
expressed in human mesenchymal cells undergoing differentiation into 1247 
adipocytes (377) and therefore circulating ACTH may be involved. 1248 
 1249 
5. Role of ACTH in lymphocytes  1250 
 1251 
The effect of ACTH synthesis and action in the immune system in an autocrine or 1252 
paracrine manner is more questionable. It has been shown that POMC is 1253 
synthesized by lymphocytes (34) and that ACTH is produced, suggesting that the 1254 
processing of POMC follows a pattern similar to the anterior pituitary, requiring 1255 
the coordinated expression of PC1/3 and the presence of a regulated secretory 1256 
pathway. There is also evidence for ACTH receptors on lymphocytes (70), 1257 
although the functional significance of this remains difficult to ascertain. More 1258 
recently it has been shown that ACTH controls growth of the thymus and that 1259 
this is not via stimulation by glucocorticoids (392). 1260 
 1261 
Figure 5: POMC processing generates numerous functional peptides 1262 
 1263 
B. The role of -MSH  1264 
 1265 
1. -MSH from the pars intermedia of the pituitary in rodents 1266 
 1267 
While rodents have provided extremely valuable data in the understanding of 1268 
POMC processing, there are some limitations which are often ignored. This is the 1269 
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case with POMC expression in the pituitary. In the adult human pituitary, which 1270 
does not have a pars intermedia (228), POMC is only expressed in corticotroph 1271 
cells in the anterior lobe. In contrast, rats and mice have a pars intermedia, 1272 
comprised primarily of melanotrophs. Processing of POMC in the pars 1273 
intermedia is similar to that in the hypothalamus, and this produces -MSH and 1274 
CLIP, rather than ACTH (233). This suggests that these smaller peptides are 1275 
released into the circulation and must be in high concentrations in the blood of 1276 
rodents. It is not clear what the functional significance of this is, as -MSH does 1277 
not bind with high affinity to the MC2R, so will not affect glucocorticoid release. 1278 
An important corollary to this is that -MSH is not produced by human 1279 
pituitaries and so will not be released from the pituitary into the blood. It is also 1280 
thought unlikely that -MSH from the hypothalamus gets into the circulation, 1281 
given it is not present in CSF in rats (312). However, there are reports of low 1282 
levels of -MSH in human blood (172, 190) which may be skin derived (see 1283 
Section IX).  1284 
 1285 
2. The role of -MSH in other tissues 1286 
 1287 
With the explosion of research into the role of the melanocortin system in the 1288 
regulation of energy balance and its implications for obesity, there is no doubt 1289 
that this is considered the most important function of -MSH (Figure 4). 1290 
However as its name suggests, the role of -melanocyte stimulating factor in 1291 
darkening of frog skin was recognized many years earlier and this formed the 1292 
basis of a bioassay for -MSH (245). Subsequently the role of melanocortin 1293 
peptides in human skin has led to the suggestion that this evolution of POMC 1294 
processing in skin is equivalent to a primeval stress axis (361). 1295 
 1296 
3. Relative roles of -MSH and its precursors: processing is key to function 1297 
 1298 
As described above there is a very well-defined set of intricate processing steps 1299 
starting from the precursor peptide, POMC, and resulting in -MSH (314). You 1300 
could hypothesize that these processing steps have evolved in order to refine the 1301 
regulation of energy balance. -MSH certainly binds to the MC4R, but with 1302 
affinity similar to des-acetyl -MSH, -MSH and ACTH (144, 260, 311) and all 1303 
four peptides have similar potency in stimulating cAMP which is required for 1304 
MC4R signaling (311).  1305 
 1306 
Central administration of -MSH to POMC null mice reduced food intake to 35% 1307 
of sham-treated animals and three days treatment reduced body weight (405). 1308 
This confirmed earlier studies where administration of -MSH to rodent brains 1309 
reduced food intake (1, 247, 251, 310). However other studies also showed that 1310 
the -MSH precursors, des-acetyl -MSH (at high doses) and ACTH, had similar 1311 
effects (4, 189). This is controversial as there is also evidence that des-acetyl -1312 
MSH injected into the brain had no effect on food intake (1, 261, 404).  1313 
 1314 
However, a recent study has generated a new mouse model where the cleavage 1315 
site in ACTH, which is necessary to generate -MSH, has been mutated. By 1316 
treating these mice with either -MSH or des-acetyl -MSH, it has highlighted the 1317 
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importance of des-acetyl -MSH, by showing it can have an equivalent effect to 1318 
-MSH in reducing body weight (259). 1319 
 1320 
If ACTH can bind to the MC4R and inhibit food intake, what is the purpose of 1321 
processing ACTH to -MSH, given this involves cleavage of ACTH to ACTH (1-17), 1322 
removal of amino acids 14-17, and then amidation and acetylation? Is it more 1323 
that the key question is which peptides are stable in the POMC neurons in the 1324 
hypothalamus and which peptides are presented to the MC4R? We have 1325 
previously shown that ACTH and POMC were present in rat CSF and regulated by 1326 
fasting, while -MSH was undetectable (312). However in hypothalamic extracts, 1327 
we found that -MSH was present at higher concentrations than POMC or ACTH 1328 
and the ratios were altered depending on energy requirement (312). Early work 1329 
suggested that -MSH’s immediate precursor, des-acetyl -MSH, was the major 1330 
product in the ARC with lesser amounts of -MSH and ACTH, while -MSH 1331 
predominated in the NTS in the brain stem (113, 114). Other studies also suggest 1332 
that des-acetyl -MSH is more abundant than -MSH in the ARC (97, 156, 182, 1333 
201, 296, 328), but not in the brainstem (103). This seems at odds with reports 1334 
that des-acetyl -MSH is relatively unstable compared to other POMC-derived 1335 
peptides (156, 272).  1336 
 1337 
It is difficult to distill a coherent mechanism from the contradictory data. There 1338 
is evidence that the acetylation of des-acetyl -MSH to generate -MSH is 1339 
regulated by leptin (156) and may be regulated by dopamine (127, 252, 410, 1340 
412), although others suggest this is not the case (95). If the final stage in the 1341 
processing pathway is important for the flux of peptides at the MC4R, this would 1342 
imply that the N-AT acts on des-acetyl -MSH at the synapse/bouton/neuronal 1343 
extremity (Figure 3) (258). Given that the POMC neurons release their peptides 1344 
in the PVN to act on the MC4R, it is tempting to speculate that future studies 1345 
should focus on the regulation of whichever peptide is released in proximity to 1346 
the MC4 receptor. 1347 
 1348 
Although much of the focus on the function of -MSH relates to suppression of 1349 
food intake, there is evidence of a role for MC4R in mediating increased energy 1350 
expenditure (48), oxygen consumption and fuel oxidation. Melanocortin 1351 
regulation of these metabolic processes appears to occur via the sympathetic 1352 
nervous system. There is some evidence for this from central injection of MT-II, a 1353 
very potent synthetic melanocortin peptide analogue, which led to loss of body 1354 
fat in rats. This was caused by enhanced thermogenesis mediated via 1355 
sympathetic nervous system outflow to white and brown adipose tissue (359, 1356 
430, 444). However the significance of this to in-situ physiological mechanisms is 1357 
not clear. 1358 
 1359 
C.  Role for -LPH as a precursor of -endorphin and -MSH  1360 
 1361 
Early work suggested that -LPH had a role in mobilizing lipid; hence its name 1362 
(326) and subsequently that it was the new aldosterone stimulating factor (240). 1363 
However over the years, it has become established that -LPH functions 1364 
primarily as a precursor for -MSH and -endorphin. In the human pituitary, -1365 
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LPH is unlikely to be further processed, as the cleavage sites require PC2 which 1366 
is not present. Therefore -LPH should be released into the human circulation in 1367 
molar equivalents to ACTH. We have previously identified -LPH as the major C-1368 
terminal POMC peptide in blood from normal subjects (148, 149). However, 1369 
several reports suggest that -endorphin is increased in human plasma with 1370 
exercise (196). While it may be that exercise specifically changes the processing 1371 
to give -endorphin, it could also be explained if it was primarily -LPH present 1372 
in the circulation and the -endorphin immunoassay cross-reacted with -LPH. 1373 
 1374 
D. The role of -MSH in energy balance 1375 
 1376 
The impact of -MSH is somewhat controversial. While -MSH is present in the 1377 
human brain, the N-terminal cleavage site to generate -MSH is not found in 1378 
rodent POMC (16, 258). Studies have shown that -MSH binds MC4R with similar 1379 
affinity to -MSH and has a similar potency (311). In addition, -MSH is able to 1380 
reduce food intake in corticosterone-supplemented Pomc null mice, although to a 1381 
lesser extent than -MSH (405). Evidence for a role for -MSH also comes from 1382 
studies in humans with mutations in -MSH. Our colleagues in Cambridge have 1383 
described an obese child with a mutation in POMC that creates a fusion protein 1384 
of -MSH and -endorphin, preventing cleavage of these peptides. One possible 1385 
hypothesis to explain why -MSH was not sufficient to prevent the obesity is that 1386 
the fusion peptide had a dominant negative effect (57). Three subsequent papers 1387 
(30, 216, 217) describe other mutations in -MSH that contribute to the evidence 1388 
that this peptide does have a role in energy balance, which should be considered 1389 
alongside that of -MSH. This is described in more detail in Section VII. 1390 
Intriguingly some Labradors noted for their voracious appetites have loss of the 1391 
-MSH sequence. This is caused by a mutation that results in a truncated POMC 1392 
which loses part of the -LPH region encompassing -MSH and -endorphin 1393 
(318). 1394 
 1395 
E. The roles of -endorphin (Figure 5) 1396 
 1397 
1. The opiate activity of -endorphin 1398 
 1399 
The highest concentration of -endorphin in the brain is found in the 1400 
hypothalamus and specifically in the arcuate nucleus, median eminence and 1401 
ventromedial border of the third ventricle (440). -endorphin (1-31) is the 1402 
major form and is active at opioid receptors (see commentary by Loh (223)). As 1403 
described above, -LPH is cleaved by PC2 to give  -endorphin which 1404 
can be further cleaved by CPE to -endorphin (1-27) and -endorphin (1-26), 1405 
which have much less analgesic activity (269). These enzymes act in secretory 1406 
granules within cells, so this implies that the cleavage of -endorphin to the C-1407 
terminally truncated -endorphin peptides is a mechanism to reduce opioid 1408 
activity in tissues where other POMC peptides are released for non-opioid 1409 
functions. Acetylation of -endorphin at its N-terminal is also a mechanism for 1410 
reduction of opioid activity (92) and this occurs in the pars intermedia of the 1411 
pituitary and in the brainstem (440). In the NTS, there are POMC expressing 1412 
neurons that primarily produce -endorphin, but there is also a considerable 1413 
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amount of , N-acetyl -endorphin (1-27), which would be much less bioactive 1414 
(103, 440). 1415 
 1416 
The first indication that -endorphin acts at opiate receptors was in 1976, when 1417 
it was shown to be 100 times more potent than morphine (132). The sequence of 1418 
met-enkephalin at its N-terminal is obviously responsible for the opiate activity, 1419 
but -endorphin has much longer-lasting effects compared to the transient 1420 
activity of the enkephalins. This has been attributed to its sequence, which 1421 
confers resistance to degradation. There is also the suggestion that the more C-1422 
terminal region of -endorphin acts in “an address function”, by presenting the 1423 
peptide to the receptor to aid specificity and potency (378). This could be 1424 
considered another advantage of the presence of a peptide within a larger pro-1425 
hormone structure. 1426 
 1427 
Given that -endorphin is produced in POMC neurons in the arcuate nucleus of 1428 
the hypothalamus, it is difficult to rationalize how POMC is stimulated to 1429 
specifically produce -endorphin to have its analgesic function in a physiological 1430 
setting. However immunohistochemical staining for -endorphin has 1431 
demonstrated its presence in nerve terminals that extend dorsally and laterally 1432 
and it can be found in the amygdala, colliculi and hippocampus. While there is 1433 
evidence for the role of -endorphin in energy homeostasis (see below), there 1434 
are very few reports which link how stimulation of POMC expression specifically 1435 
drives analgesia without releasing the melanocortin peptides, which should have 1436 
an important role in increasing energy expenditure and inhibiting food intake. It 1437 
is tempting to speculate that this is where a hormone precursor is providing 1438 
different peptides with different roles but with a common theme of coordinating 1439 
a response to pain as a self-preservation mechanism.  1440 
 1441 
In a very elegant study, Rubinstein et al. produced mice with a targeted mutation 1442 
that inserted a premature stop codon in the POMC gene to prevent the synthesis 1443 
of -endorphin (334). These mice were not able to mount an analgesic response 1444 
to a mild swim stress and had a compensatory upregulation of other pain 1445 
inhibitory pathways. This does suggest that a stress activation of POMC would 1446 
produce an analgesic response mediated by -endorphin. 1447 
 1448 
2. Role of -endorphin in reproductive function 1449 
 1450 
Early work on endogenous opioid peptides, including -endorphin, indicated 1451 
that they inhibited gonadotropin secretion (133) and the opioid antagonist, 1452 
naloxone, stimulated luteinizing hormone release in men and women (122, 315). 1453 
The mechanism was elucidated in studies in rats and involves the release of 1454 
hypothalamic -endorphin into hypophysial portal blood, which is stimulated by 1455 
ovarian steroids (342) and inhibited by testosterone (418). An interesting aspect 1456 
of the precursor role of POMC is that in producing both -MSH and -endorphin 1457 
there is the potential to have two peptides which antagonize each other. -MSH 1458 
blocks both stress-induced and -endorphin-stimulated release of prolactin in 1459 
rats (267). In monkeys, -MSH has a similar effect on -endorphin induced 1460 
prolactin and blocks the -endorphin mediated decrease in luteinizing hormone 1461 
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(419). 1462 
 1463 
3. Hypothalamic -endorphin function and regulation of energy balance  1464 
 1465 
Given that many of the component peptides of POMC have a role in energy 1466 
balance, it is important to consider whether -endorphin may also be involved in 1467 
some capacity. Mechanisms regulating the release of melanocortin peptides from 1468 
POMC in hypothalamic neurons will generate -endorphin. However, it is 1469 
important to consider whether the -endorphin actions are synergistic with 1470 
those of the melanocortins, or whether they are not commensurate, implying 1471 
that they would oppose each other. If it is the latter, then there may be 1472 
processing mechanisms to inactivate -endorphin when melanocortins are 1473 
activated and vice versa. Although inactivation by acetylation of -endorphin is 1474 
not thought to occur in the hypothalamus (258), it may be that processing to -1475 
endorphin (1-27) and -endorphin (1-26) is a mechanism which at least reduces 1476 
its activity (269). As early as the 1920’s there were suggestions that the 1477 
endogenous opioid system was involved in the regulation of food intake and 1478 
body weight, with morphine causing a decrease in body weight but a “voracious” 1479 
appetite. However, there is a lot of contradictory data in both animal and human 1480 
studies (12). Nevertheless, more recent compelling data from a study of mice 1481 
with deletion of -endorphin showed that the male mice were obese and 1482 
hyperphagic (9). This suggests that loss of -endorphin results in hyperphagia, 1483 
highlighting an unexpected anorexigenic effect of endogenous -endorphin, 1484 
which parallels the melanocortin actions of the other peptides derived from 1485 
POMC. Nevertheless, -endorphin is involved in a motivational reward behavior 1486 
in non-deprived conditions (227) and other studies have found stimulatory 1487 
effects on feeding (36), suggesting that there are two different roles for -1488 
endorphin depending on the circumstances. This concept would support the 1489 
finding that cannabinoid-induced feeding is dependent on -endorphin (203). 1490 
 1491 
In considering the endogenous POMC activity, it is difficult to rationalize the 1492 
concept that several peptides are produced simultaneously which have opposing 1493 
actions. This is nevertheless implied by the fact that -MSH and -MSH causes 1494 
anorexigenic actions while, -endorphin stimulates feeding. It may be that the 1495 
regulation of POMC processing events underpins how effective POMC peptides 1496 
are in coordinately regulating energy balance. Dutia et al. gave -endorphin by 1497 
intracerebroventricular injection and compared food intake and body weight 1498 
gain in rats when an analogue of -MSH (NDP-MSH) was co-administered (112). 1499 
When -endorphin was given over 2-6 hours, it stimulated food intake and it 1500 
reversed the inhibitory effect of NDP-MSH on food intake. However with more 1501 
chronic dosing over 4-7days, -endorphin failed to antagonize the effects of NDP-1502 
MSH.  1503 
 1504 
This still leaves several questions regarding the mechanisms that balance the 1505 
effects of melanocortins and -endorphin on energy balance. Given there are so 1506 
many regulatory stages in the processing of POMC, it suggests that processing 1507 
has evolved in such a way to provide subtle regulation of active peptides in the 1508 
hypothalamic neurons. 1509 
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 1510 
4. Role of -endorphin in skin 1511 
 1512 
It has also been suggested that -endorphin has very specific roles in the skin 1513 
and this is described in Section IX. 1514 
 1515 
F. Roles for the N-POMC peptides (Figure 5) 1516 
 1517 
Compared with the other regions of POMC, there are fewer reports on functional 1518 
roles for the POMC-derived peptides that are linked to the N-terminal of ACTH, at 1519 
least in the human. It may be that there has been relatively less research in this 1520 
area, rather than that the peptides do not have physiological roles. To our 1521 
knowledge, there are relatively few mutations in this region that inform function, 1522 
and in the human these are involved in obesity (128). However, many of the 1523 
mutations in this region would also affect the translation of POMC. 1524 
 1525 
1. The role of N-terminal POMC peptides in adrenal growth 1526 
 1527 
There is a wide body of data from the 1980s, described in detail in a review by 1528 
Bicknell (27), which suggests that a fragment of human N-POMC increases rat 1529 
adrenal gland weight and mitotic index (124). Previous work had indicated that 1530 
the full-length N-POMC peptide (1-76 in humans and 1-74 in rats) was not active 1531 
(123). The most effective fragment was N-POMC (1-28), which had been isolated 1532 
from human pituitaries as part of the purification of growth hormone (124) but 1533 
was known to be a purification artefact so presumably didn’t exist normally in 1534 
pituitaries (246). Subsequently in rats, N-POMC (1-28) partially regenerated 1535 
adrenal glands which had been enucleated (125). Further work provided 1536 
evidence that the N-POMC (1-28) peptide stimulated cell division in primary 1537 
bovine adrenal cells, Y1 cells and human adrenal tumor cells (NCI-H295-R) 1538 
(131). However, when N-POMC (1-28) was given to mice with a null mutation in 1539 
the Pomc gene, there was no effect on adrenal growth, and no change in adrenal 1540 
morphology, in a setting where ACTH (1-24) caused adrenocortical hypertrophy 1541 
(75).  1542 
 1543 
Later work with Y1 adrenal cells has extended the analysis of how synthetic N-1544 
POMC (1-28) stimulates the pathways involved in cell proliferation (reviewed in 1545 
(226)). There is evidence that N-POMC (1-28) increases phosphorylation of 1546 
ERK1/2 as well as activation of MEK and c-RAF (303). This has been 1547 
complemented with studies in isolated rat adrenal cells showing activation of the 1548 
ERK pathway by N-POMC (1-28) (241) and in vivo in rat adrenal cortex where 1549 
synthetic N-POMC (1-28) up-regulated proliferation and blocked apoptosis 1550 
(401).  1551 
 1552 
In parallel with the earlier studies described above, the group led by Phil Lowry 1553 
injected antisera raised to N-POMC (1-28) and to a synthetic 3-MSH peptide into 1554 
rats. They found different effects on compensatory adrenal growth in the contra-1555 
lateral gland, following the removal of the other adrenal gland (229). They 1556 
suggested that N-POMC (1-48/49) stimulates DNA synthesis and mitogenesis, 1557 
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while a second region in N-POMC (i.e. 3-MSH) increases RNA synthesis and 1558 
hypertrophy (229).  1559 
 1560 
In essence, the early work showed that full-length N-POMC was not active in 1561 
stimulating adrenal growth, but that the shorter N-POMC (1-28) was able to 1562 
stimulate adrenal gland mitogenesis. This led to the hypothesis that N-POMC had 1563 
to be cleaved to have effects on adrenal growth. N-POMC (also called pro--MSH) 1564 
can be measured in human plasma (58, 148, 160) and is one of the main 1565 
products secreted from rat pituitary corticotrope cells (117, 181), indicating that 1566 
it is likely that this is the major N-terminal POMC peptide in the circulation. 1567 
Therefore any cleavage of N-POMC would occur at the target cells i.e. at the 1568 
adrenal cortex. The discovery of a rat adrenal gland derived trypsin-like enzyme 1569 
called adrenal secretory protein (AsP) is described in detail in Bicknell (27). This 1570 
enzyme cleaves between valine and methionine and so would generate N-POMC 1571 
(1-52) which can stimulate adrenal mitogenesis (28). However, there is evidence 1572 
that the human equivalent of AsP does not have a physiological role in regulation 1573 
of adrenocortical growth because of low expression of the enzyme in human 1574 
adrenal tissue (158).  1575 
 1576 
It is difficult to resolve some of the inconsistencies in the understanding of the 1577 
role of N-POMC peptides, because the large body of data has used different 1578 
peptides and various models, which are not always comparable. One possibility 1579 
may be that N-POMC (1-28) is an extraction artefact and there is evidence that N-1580 
POMC (1-48/49) may not circulate to get to the adrenals because the O-1581 
glycosylation at Thr45 inhibits cleavage at Arg49-Lys50, which is a likely site for 1582 
pro-hormone convertases (348). The presence of full length N-POMC in human 1583 
plasma substantiates the evidence of a lack of cleavage in human pituitary cells. 1584 
Therefore, if fragments of the N-POMC peptides play a role in adrenal 1585 
mitogenesis, it would have to be after cleavage at the adrenal gland. However, it 1586 
seems that the human equivalent of AsP is not capable of this role.  1587 
 1588 
It may be that stimulation of growth of the adult adrenal cortex by POMC 1589 
peptides is more physiologically relevant than it is in the fetus. There is evidence 1590 
for this in Pomc null mice where the adrenal glands undergo atrophy after birth. 1591 
Transplantation of these adrenals into wild-type mice rescues growth and 1592 
corticosterone production (188). This implies that some POMC-derived peptides 1593 
restore growth and steroid secretion in mice. However it is not possible to 1594 
determine which POMC-derived peptides are responsible, although there is 1595 
evidence for and against ACTH (reviewed in (27, 226)).  1596 
 1597 
2. The role of N-terminal POMC peptides in salt-sensitive hypertension  1598 
 1599 
There is some intriguing evidence about the role of -MSH and its effects on 1600 
natriuresis and control of blood pressure (reviewed in (174)). Several studies 1601 
have shown that -MSH can have a hypertensive effect, acting via a central 1602 
mechanism. However other studies have indicated the opposite effect. In PC2 1603 
knockout mice, where there is decreased -MSH, hypertension occurred on a 1604 
high salt diet and treatment with -MSH prevented the increased mean arterial 1605 
pressure. Absence of the Mc3r gene also caused a hypertensive effect (268). In 1606 
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addition, there is some suggestion that -MSH acts directly on MC3R in the 1607 
kidney to play a role in natriuresis, while other evidence points to a central role 1608 
acting via sympathetic outflow on the periphery.   1609 
 1610 
Our understanding of these mechanisms is complicated by the fact that in mouse, 1611 
rat and guinea pig, -MSH may not exist as a separate peptide, because the C-1612 
terminal region does not have the dibasic amino acids to allow cleavage from the 1613 
N-POMC region (114). In the studies described above on adrenal growth, it was 1614 
presumed that the full length N-POMC is released from the anterior pituitary and 1615 
therefore -MSH would only be released from the pars intermedia of the 1616 
pituitary, which is rudimentary in humans. Therefore, the relevance of these 1617 
mechanisms in humans needs further clarification. It is tempting to speculate 1618 
that if there is an enzyme which cleaves N-POMC at the adrenal to produce a 1619 
peptide which promotes adrenal cortex mitogenesis, then the same enzyme may 1620 
also be present in the kidney to generate peptides that stimulate natriuresis. 1621 
 1622 
The evolution of POMC as a precursor of peptides with multiple actions leads to 1623 
the question of whether it would be valuable to have a response that releases 1624 
stress hormones and a natriuretic hormone that decreases blood pressure. 1625 
Perhaps this overlooks the subtlety of the system and these two responses have 1626 
evolved to respond to different stimuli in different tissues. 1627 
 1628 
3. Role of -MSH in energy balance 1629 
 1630 
While there is clear evidence that -MSH plays a role in decreasing food intake, it 1631 
is more difficult to determine the relative importance of -MSH peptides and the 1632 
net effect of coordinated processing of POMC. It is predicted that 3-MSH and 2-1633 
MSH can be produced in the hypothalamus in humans, but that 3-MSH cannot be 1634 
processed to 2-MSH or 1-MSH in rats and mice because of the lack of suitable 1635 
dibasic amino acids (114). It is also difficult to find direct evidence that indicates 1636 
a role for these peptides in energy balance. 2-MSH binds to the mouse MC3R 1637 
(and MC5R) better than to other MCRs (184) and the MC3R is important for 1638 
energy homeostasis (reviewed in (258)), although it does not appear to have a 1639 
role in food intake (1). However -MSH has comparable binding activity to -1640 
MSH at the human MC3R (reviewed in (198)) so it is not clear which is the 1641 
natural ligand at least in the hypothalamus.  1642 
 1643 
G.  Does joining peptide have a role? 1644 
 1645 
There is very little evidence for a role for joining peptide. There was a suggestion 1646 
that a peptide identical to joining peptide (1-18) stimulated production of 1647 
dihydro-epiandrostenedione (DHEA) from adult human adrenal cells (297) and 1648 
was therefore designated as the missing cortical androgen-stimulating hormone 1649 
(CASH). However, other studies have failed to find evidence for this in adult 1650 
(302) or fetal (330) adrenal cells. 1651 
 1652 
 1653 
 1654 
 35 
VII. DISORDERED PROCESSING IN THE HYPOTHALAMUS; CHILDREN 1655 
WITH OBESITY 1656 
 1657 
A. Mutations in POMC lead to obesity 1658 
 1659 
The processing of human POMC is very different in the hypothalamus to that in 1660 
the pituitary. In the hypothalamus it involves the sequential effects of two pro-1661 
hormone convertases and numerous post-translational modifications to 1662 
generate the melanocortin peptides, -, - and γ-MSH. Both - and -MSH are 1663 
recognized to have important roles in the regulation of energy balance and either 1664 
loss of POMC or disruption of pro-hormone processing results in severe obesity. 1665 
The following examples in children give insights into the importance of the pro-1666 
hormone and the requirements for the different melanocortin peptides. 1667 
 1668 
1. Early studies linking mutations in POMC to obesity 1669 
 1670 
The earliest reports suggesting mutations in the POMC gene were associated 1671 
with obesity came from linkage studies in Mexican Americans. In this analysis, 1672 
patients with increased leptin levels had a polymorphism which was mapped to 1673 
chromosome 2p21, where POMC is located (76). Another linkage study showed 1674 
that French subjects had a similar mutation in chromosome 2p21, demonstrating 1675 
that the mutations were found in other ethnicities and cultural backgrounds 1676 
(157). These studies were carried out in advance of the POMC gene deletion in 1677 
mice and gave an initial association between mutations in POMC and increases in 1678 
leptin and fat mass. 1679 
 1680 
2. Mutations leading to global loss of POMC peptides  1681 
 1682 
The strongest evidence for a link between mutations in POMC and obesity comes 1683 
from children who have either homozygous or compound heterozygous 1684 
mutations in the gene, leading to the absence of all melanocortin peptides. One of 1685 
the first patients described had a homozygous C  T mutation at 3804 in exon 2, 1686 
which is in an untranslated region. This created an additional out of frame start 1687 
codon which abolished the translation of wild-type POMC. The clinical features 1688 
observed in the patient are linked to the loss of binding of POMC derived 1689 
peptides to the MCRs in specific tissues. The patients had red hair, indicating lack 1690 
of binding to MC1R, they were hypocortisolemic due to absence of ACTH binding 1691 
to MC2R and obese due to deficiency in MSH binding to MC3R and MC4R (207). 1692 
The same group later described another patient with the same mutation and 1693 
phenotype (208). 1694 
 1695 
Heterozygous mutations in the non-coding region have also been described and 1696 
are associated with obesity. By screening obese populations, two patients were 1697 
found with different heterozygous mutations in exon 2 of the POMC gene. These 1698 
have been implicated in disruption of POMC sorting to the regulatory secretory 1699 
pathway. Examination of the processing in these patients indicated that the 1700 
mutations had interfered with the entry of POMC into the normal regulated 1701 
secretory pathway (86). This disruption to the processing of POMC and the 1702 
reduction in processed peptides was associated with the development of obesity.  1703 
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 1704 
3. Mutations in the N-terminal region of POMC 1705 
 1706 
In the initial paper describing children with a lack of POMC, one of the patients 1707 
showed two separate mutations in exon 3 of POMC, giving a compound 1708 
heterozygous mutation. The first mutation was a G  T substitution at 1709 
nucleotide 7013, leading to a premature stop codon at codon 79. The second 1710 
mutation was a single base pair deletion at nucleotide 7133, predicating a frame 1711 
shift which would disrupt ACTH and -MSH binding motifs as well as inserting a 1712 
stop codon at 131. Similar to the patient with the homozygous mutation in the 1713 
non-coding region of POMC, this patient also had red hair, decreased cortisol and 1714 
obesity (207). As both - and -MSH are disrupted by these mutations, it is 1715 
difficult to clearly discern their relative importance.  1716 
 1717 
The same research group later characterized two further children who also had 1718 
mutations in the N-terminal region of POMC. They both had compound 1719 
heterozygote mutations with a frame shift or a premature stop codon, preventing 1720 
translation of the region with ACTH and the MSH peptides. These patients were 1721 
obese and also had red hair due to the lack of melanocortin peptides (208).  1722 
 1723 
The first patient to be described without red hair was a Turkish child with a 1724 
novel homozygous frame shift mutation at nucleotide 6906, though he did have 1725 
dark red follicles. This mutation would be predicted to lead to a loss of all POMC 1726 
derived peptides. As with the other patients, this child had severe hyperphagia 1727 
leading to early onset severe obesity. (129). The association between 1728 
heterozygous mutations in POMC and obesity was strengthened in this study. Of 1729 
the 12 heterozygous relatives of the child, 11 were overweight or obese (129). 1730 
 1731 
Other novel mutations in the ACTH region of POMC have been described, where 1732 
the POMC derived peptides are still immunoreactive, but have lower biological 1733 
activity (339). A more recent study described a patient with red hair who had 1734 
moderate obesity at an early age, with undetectable plasma ACTH and serum 1735 
cortisol. This index case was a compound heterozygote with one mutation in the 1736 
N-terminal region of POMC and the second mutation upstream from the coding 1737 
domain. The latter affected a region involved in translation of the protein such 1738 
that there was preserved but markedly diminished levels of wild-type POMC 1739 
transcript (7).  1740 
 1741 
Other patients have been described with mutations in this region. The hair 1742 
colour phenotype has not been observed in all patients, even when mutations 1743 
were predicted to lead to an absence in -, -, and -MSH as well as -endorphin, 1744 
(71, 248). However, all patients identified with deletions in the N-terminal of 1745 
POMC have severe obesity (71, 167, 248, 254).  1746 
 1747 
4. Mutations in the -MSH region  1748 
 1749 
There are very few reports of mutations in this region. Studies examining 1750 
patients with severe obesity have occasionally identified heterozygous mutations 1751 
in the -MSH region of POMC. However, these mutations were rare in the obese 1752 
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population and were also found in the lean control population, indicating that 1753 
the loss of one allele of -MSH can be tolerated in the context of energy balance 1754 
(109, 216), and/or that -MSH plays a more important role. There is some 1755 
evidence to substantiate this in the section below. 1756 
 1757 
5. Defects in the -MSH and -endorphin regions of the POMC gene 1758 
 1759 
Mutations in the -MSH region of POMC have strong associations with obesity. 1760 
During screening studies of patients with early onset obesity, patients have been 1761 
described with a heterozygous R236G mutation in the highly conserved dibasic 1762 
processing site between -MSH and -endorphin (46, 57, 254). This mutation led 1763 
to the formation of a fusion protein of the 2 peptides, which was able to bind 1764 
MC4R, but was less functional (57). These patients have the characteristic 1765 
hyperphagia and early onset obesity associated with reduced binding to MCRs 1766 
(57). Interestingly, there were relatives of the index patient who were also 1767 
heterozygous for the mutation. Although they did not have the severity of obesity 1768 
observed in the index case, they were more likely to be overweight than a 1769 
relative without the mutation (57). 1770 
 1771 
Another mutation identified in the -MSH region is the Y221C mutation. This 1772 
altered form of -MSH was able to bind MC4R, but was unable to activate it. This 1773 
mutation was strongly associated with obesity, as 11 of 13 relatives with the 1774 
same heterozygous mutation were obese. However, some non-carriers were also 1775 
found to be overweight (30, 216), indicating that at least in this kindred, the 1776 
obesity phenotype cannot solely be as a result of the mutation in -MSH.  1777 
 1778 
6. Variants in the -MSH region of POMC 1779 
 1780 
The have been multiple reports of many subjects with 6, 9 and 19 base pair 1781 
insertions in the -MSH region of POMC, in screening studies investigating POMC 1782 
mutations in obese patients from different ethnic backgrounds. Although these 1783 
insertions have been found in the obese cohort, they have also been identified in 1784 
the normal weight participants making it difficult to associate these insertions 1785 
with obesity (116, 167, 254, 340). 1786 
 1787 
B. Mutations in PC1/3 cause obesity 1788 
 1789 
Many of the early papers characterizing patients with mutations in PC1/3 1790 
predate the discovery of leptin and were seminal in defining novel monogenic 1791 
causes of obesity. As with POMC mutations, homozygous or compound 1792 
heterozygous mutations in PC1/3 cause severe hyperphagia leading to early 1793 
onset obesity (130, 179, 180, 239, 274). This is most likely related to the 1794 
abnormal processing of POMC. These patients have been found to have high 1795 
levels of POMC (130, 179, 180, 274), but with normal circulating ACTH or normal 1796 
to low cortisol levels (130, 179, 239, 274). The ACTH has been shown to be 1797 
authentic, bioactive ACTH (179), which was surprising since PC1/3 mutations 1798 
would be expected to prevent cleavage of POMC to ACTH. This indicates that in 1799 
some instances, other enzymes such as PC5A, furin and PACE4 may be able to act 1800 
in place of PC1/3. 1801 
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 1802 
As PC1/3 cleaves numerous pro-peptides, a plethora of other clinical phenotypes 1803 
were noted in these patients. For example, with an impairment of the cleavage of 1804 
pro-insulin to insulin, these patients also had abnormal glucose metabolism.  1805 
(130, 179, 274).  1806 
 1807 
Initial analysis of heterozygous PC1/3 loss was not thought to have any 1808 
metabolic sequelae, as heterozygous parents of index subjects without a 1809 
functional copy of PC1/3 were not obese (130, 179, 180). However, further 1810 
human genetic analysis, both of the PCSK1 gene (85) and SNPs in this gene (21), 1811 
suggest this may not be the case. For example, a nonsense mutation in PCSK1 has 1812 
been reported to cause dominantly inherited obesity (306) even though in vitro 1813 
bioactivity predicts as little as 20% reduction in enzyme activity (306). 1814 
 1815 
PC1/3 mutations appear to be the only mutations in POMC processing enzymes 1816 
associated with obesity in humans. Surprisingly, to date, no obese patients have 1817 
been described with mutations in PC2. A screening study of families with type 2 1818 
diabetes found a mutation in carboxypeptidase E, but the authors concluded that 1819 
the mutation was not a significant cause of the diabetes (63).  1820 
 1821 
 1822 
VIII.  DISORDERED PROCESSNG IN THE HYPOTHALAMUS; MICE WITH 1823 
OBESITY 1824 
 1825 
A. Global deletion of POMC 1826 
 1827 
To investigate the role of POMC and its processed peptides, mice with a global 1828 
knockout of POMC have been developed. There have been two separate 1829 
approaches to removing POMC, both involving the deletion of exon 3. The 1830 
original model left the possibility that the N-terminal fragments of POMC could 1831 
still be transcribed (437), but the later version ensured this was not possible 1832 
(56). Both strains experienced some embryonic lethality (56, 437), indicating the 1833 
importance of POMC in development and maturation in utero.  1834 
 1835 
Overall, the loss of POMC has a significant impact on the metabolic phenotype of 1836 
the mouse with much concordance between reports. Pomc null mice develop 1837 
obesity from around 2 months of age, have increased fat and lean mass (56) and 1838 
an increase in body length (437). The obesity seen in the original model 1839 
persisted when the mutant allele was backcrossed onto a C57Bl/6 background 1840 
(371). Both murine models were hyperphagic on low and high fat diets (56, 437) 1841 
with administration of -MSH to one of the Pomc null models able to ameliorate 1842 
the hyperphagia and bring about weight loss (437). A lower resting oxygen 1843 
consumption seen in one model (56) may have an additional role in the 1844 
development of obesity. Pomc null mice have a normal glucose tolerance but they 1845 
have an increased sensitivity to insulin, likely due to their corticosterone 1846 
deficiency (170).   1847 
 1848 
Pomc null mouse models have also highlighted the importance of the POMC 1849 
derived peptides in the maintenance of adrenal gland development. There has 1850 
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been controversy around which peptides contribute to adrenal gland growth, 1851 
with evidence for both ACTH and N-POMC peptides as key to the process. At 1852 
birth, POMC knockout mice have adrenal glands that are morphologically 1853 
indistinguishable from those of their wild-type littermates (188), but by 1854 
adulthood, these mice have either no macroscopically determinable (437) or 1855 
very small but identifiable (56, 371) adrenal glands. The lack of POMC in these 1856 
mice results in no circulating ACTH, and consequently  they lack circulating 1857 
corticosterone (56, 371, 437), even prior to atrophy of the adrenal glands (188). 1858 
Acute administration of ACTH appeared insufficient to induce corticosterone 1859 
production (188), however a longer treatment period normalized adrenal weight 1860 
and circulating corticosterone (74). In contrast, treatment with POMC (1-28) did 1861 
not “rescue” the adrenal glands (75). Furthermore, when adrenal glands from 1862 
knockout mice were transplanted into POMC-intact mice they were able to 1863 
produce corticosterone (188) showing the importance of POMC derived peptides 1864 
in maintenance of adrenal gland corticosterone production. Together these 1865 
results demonstrate that ACTH is required to maintain adrenal gland function.  1866 
 1867 
In these Pomc null mouse models, the impact of loss of hypothalamic Pomc on 1868 
body weight may have been tempered by lack of pituitary ACTH and therefore 1869 
lack of corticosteroids. This has led to an interesting phenotype of obesity in the 1870 
absence of circulating glucocorticoids. Therefore to investigate the full impact of 1871 
the loss of POMC in the presence of glucocorticoids, two approaches have been 1872 
reported: (1) administration of corticosterone in drinking water and (2) 1873 
restoration of POMC in the pituitary to enable ACTH production and then   1874 
corticosterone synthesis. In the first approach, corticosterone supplementation 1875 
normalized the circulating corticosterone in Pomc null mice, but significantly 1876 
increased body fat and body weight further. (73). This was associated with a 1877 
significant increase in the expression of the MC4R antagonist, AgRP (73). In the 1878 
second approach, Malcolm Low’s lab introduced a POMC transgene into the 1879 
pituitary of POMC knockout mice to rescue POMC derived peptides in the 1880 
pituitary (372). In contrast to the global POMC knockout mice, this transgenic 1881 
line had large adrenal glands and while female mice had a normal corticosterone 1882 
diurnal rhythm, males had both exaggerated peak and nadir levels leading to 1883 
overall higher levels of corticosterone, in keeping with a Cushing’s type 1884 
syndrome (373). Compared to POMC knockout mice, these pituitary rescued 1885 
POMC knockout mice were even more hyperphagic and developed a greater 1886 
degree of obesity. Additionally, they developed hyperglycaemia and insulin 1887 
resistance with hepatic steatosis (372), likely to be due to the excess pituitary 1888 
ACTH increasing glucocorticoids. 1889 
 1890 
To elucidate the role of hypothalamic POMC, and in particular -MSH, at 1891 
different stages in the evolving obesity seen in global POMC deficiency, another 1892 
murine model was established that allowed for re-expression of hypothalamic 1893 
POMC at different ages in global Pomc null mice. As one might expect, restoration 1894 
of neuronal POMC and -MSH expression at all ages effectively normalized the 1895 
hyperphagia in Pomc null mice. However, the effectiveness of this treatment to 1896 
normalize body weight and diminish adipose mass declined progressively as the 1897 
age at which Pomc was inducted increased, with a diminished impact on body fat 1898 
reduction in older, and hence fatter, mice (45). Finally, in yet another mouse 1899 
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model, re-expression of Pomc solely in hypothalamic neurons expressing the 1900 
leptin receptor was sufficient not only to normalize the increased body weight 1901 
and food intake observed in the global Pomc null mice but also to correct 1902 
alterations in glucose homeostasis and locomotor function (212). 1903 
 1904 
Together, a range of mouse models with genetically altered POMC have helped to 1905 
elucidate the roles of POMC in many aspects of adrenal development and 1906 
metabolic homeostasis. Perhaps surprisingly however a distinct coat color 1907 
phenotype was only clearly seen in POMC null mice on a 129 background (56).  1908 
 1909 
B.  Loss of PC1/3: implications for POMC 1910 
 1911 
1. PC1/3 null mice 1912 
 1913 
The importance of POMC as a precursor compared to the derived peptides 1914 
should be determined by the knockout of PC1/3, as this has the potential to 1915 
produce POMC in vivo without any of the peptides derived from it. However, the 1916 
reality has proved much more complex, because of concomitant lack of 1917 
processing of other peptides and the potential for cleavage of POMC by other 1918 
peptidases. 1919 
 1920 
The role of PC1/3 in the cleavage of POMC in vivo was first elucidated in PC1/3 1921 
null mice developed in 2002. These mice have increased unprocessed POMC in 1922 
the pituitary and a lack of processing to ACTH (291, 449). Surprisingly, even 1923 
though there was an absence of ACTH, there was no difference in corticosterone 1924 
(449), suggesting that perhaps the higher levels of POMC could compensate for 1925 
the lack of ACTH. However, this has not been confirmed by other studies (387). 1926 
Relative levels of other POMC-derived peptides were not altered in PC1/3 null 1927 
mice (291), indicating some adaptation or compensation. Either PC2 or another 1928 
enzyme must be in place to maintain the levels of other POMC-derived peptides. 1929 
 1930 
The first PC1/3 null mice were not obese, unlike patients with mutations in the 1931 
gene (see Section VII). This may not be as surprising as it first seems, because the 1932 
mice have unaltered levels of POMC cleavage products including MSH. PC1/3 1933 
null mice also have other metabolic abnormalities, including undetectable levels 1934 
of insulin in pancreatic islets as they are unable to cleave pro-insulin to insulin 1935 
(448).Intriguingly, despite this marked hyperproinsulinemia the mice appear not 1936 
to have an impairment of glucose tolerance.  (449).  1937 
 1938 
A second PC1/3 null mouse was developed by Seidah and Chrétien in 2007. 1939 
However this mouse was embryonic lethal and therefore could not be used in 1940 
further experiments (243). 1941 
 1942 
2. PCSK1-N222D hypomorph mouse 1943 
 1944 
Interestingly, a single point mutation in the Psck1 gene led to a mouse with an 1945 
obese phenotype, similar to that seen in patients with these mutations. This 1946 
Pcsk1-N222D hypomorph mouse had a 60% reduction in PC1/3 activity (221). 1947 
Unlike the PC1/3 knockout mouse, this strain was a normal size due to its ability 1948 
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to process pro-GHRH (386). These mice developed obesity and by 6 months, 1949 
males were 32% heavier and females 68% heavier then their wild-type 1950 
littermates as a result of increased fat mass (221).  1951 
 1952 
In the hypothalamus, the expression of the Pomc gene in Pcsk1-N222D 1953 
hypomorph mice was similar to wild-type mice, but they had a 45% reduction in 1954 
-MSH, which may have a played a role in the observed hyperphagia and could 1955 
have contributed to the obesity (221). There was also impaired processing in the 1956 
pituitary, in that they had increased pro-ACTH levels compared to wild-type mice 1957 
(386). Surprisingly the Pcsk1-N222D hypomorph mice had a slight elevation in 1958 
ACTH which supports the theory that processing of POMC to ACTH may not be 1959 
completely dependent on PC1/3 (221).  1960 
 1961 
C.  PC2 knockout mice: Implications for POMC processing  1962 
 1963 
The PC2 knockout strain was developed in 1997 by deletion of exon 3. The mice 1964 
appeared normal at birth, but grew at a slightly slower rate and had normal fat 1965 
distribution and mass (140). In addition, PC2 null mice had high circulating 1966 
ACTH, but normal circulating corticosterone (300). Abnormalities in the 1967 
processing of POMC in both the pituitary and hypothalamus were noted. The 1968 
pituitary had reduced Pomc mRNA levels, but both the glycosylated and 1969 
unglycosylated forms of POMC protein were increased (213). This was 1970 
accompanied by increased pituitary ACTH concentrations (213, 300) and higher 1971 
numbers of secretory granules (213), which was consistent with the elevated 1972 
POMC and ACTH concentrations. The pituitaries from PC2 knockout mice also 1973 
contain increased amounts of -LPH, and reduced amounts of its cleavage 1974 
products -LPH and -endorphin due to the lack of processing (213). Depending 1975 
on the method of detection, -MSH was found to be either absent (213) or very 1976 
diminished (161). Furthermore, des-acetyl -MSH, di-acetyl -MSH forms and 1977 
CLIP were also found at much lower levels than in wild-type mice (161). 1978 
  1979 
In the hypothalamus, the levels of POMC were not altered. Again, similar to the 1980 
pituitary, there was a large reduction in the cleavage of -LPH to -LPH and -1981 
endorphin, but with still about a third of the normal conversion (6), indicating 1982 
that although PC2 is the primary processing enzyme, other pathways are 1983 
possible. Of the -endorphin (1-31) present, there was a reduced amount of 1984 
processing to -endorphin (1-27) and -endorphin (1-26) (6). Like the pituitary, 1985 
-MSH, des-acetyl -MSH and CLIP were all absent in the hypothalamus (290, 1986 
443). It would be interesting to investigate the effects of deletion of both PC1/3 1987 
and PC2 on POMC processing, however the double knockout strain was lethal 1988 
(420).  1989 
 1990 
D. CPE gene deletion: implications for POMC 1991 
 1992 
CPEfat/fat mice have a missense mutation in the gene for CPE at Ser202. 1993 
Investigation of this identified a problem with the translation of CPE, as the 1994 
mRNA levels were normal, but the protein was absent (263). Phenotypically the 1995 
mice had late onset obesity and were hyperglycemic, but responded to 1996 
exogenous insulin, demonstrating that pro-insulin processing was defective 1997 
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(263). Although CPE was completely absent in CPEfat/fat mice, there was other 1998 
carboxypeptidase activity in some tissues. In the pituitary, it was at about 6%, in 1999 
brain at 50-57%, but in heart and duodenum there was no reduction in activity. 2000 
This was most likely due to the activity of CPD, CPN and/or CPM (137).  2001 
 2002 
The studies carried out on POMC in CPEfat/fat mice have helped elucidate the role 2003 
of CPE as a sorting enzyme, controlling the release of POMC and its processed 2004 
products between constitutive and regulated pathways. CPEfat/fat mice had 2005 
increased constitutive POMC and ACTH release from their pituitaries (83, 356, 2006 
357). They also had very few of the small cleavage products of POMC and, as 2007 
most of this processing occurs in regulated secretory granules, this is consistent 2008 
with these mice not being able to sort POMC into these secretory granules. 2009 
Therefore in CPEfat/fat mice, due to the lack of CPE, POMC is mis-sorted and 2010 
mainly released constitutively.  2011 
 2012 
Additionally, many studies have examined the processing of POMC in the 2013 
CPEfat/fat mice. POMC accumulated in the pituitary in these mice at a level of 24-2014 
fold greater than WT controls (357), but it was poorly processed to ACTH, with 2015 
only 30% of the expected amount (83, 357). There were also reductions in the 2016 
levels of -MSH, -endorphin, -LPH and CLIP (23). This may be because there is 2017 
mis-sorting or because of altered levels of PC1 and PC2 in different brain regions 2018 
of CPEfat/fat mice (23, 220). These changes in peptide levels in the hypothalamus 2019 
had a functional effect on the body weight phenotype. There was a reduction in 2020 
peptides like -MSH, which could lead to an increase in body weight, but no 2021 
change in the hypothalamic levels of those known to do the opposite, such as -2022 
endorphin (1-31) (442). Overall this may enhance the obesity phenotype. 2023 
 2024 
More recently the Loh group generated a CPE global knockout mouse. This strain 2025 
is similar to the CPEfat/fat mice, in that they had late onset obesity, hyperglycaemia 2026 
and higher levels of pro-insulin than insulin (53). Very little work has been 2027 
carried out in these mice in relation to POMC processing. However, they were 2028 
found to have reduced hypothalamic -MSH. In addition, the pituitary levels of 2029 
ACTH and -MSH were also reduced, with higher levels of unprocessed POMC in 2030 
the pituitary (52). Overall it appears that the global deletion of CPE gives a very 2031 
similar phenotype because of the same reduction in protein expression as seen 2032 
with the single point mutation in the CPEfat/fat mice.  2033 
 2034 
 2035 
IX.  POMC PROCESSING IN THE SKIN 2036 
 2037 
Given that the MSH peptides were named melanocyte stimulating hormones 2038 
after their role in skin (55, 358), it is not surprising that there is a long history 2039 
concerning the production and the roles of POMC and constituent peptides. The 2040 
POMC peptides were detected in the skin before it was obvious that they came 2041 
from a common precursor (26, 364, 366, 397, 414) and some of the work 2042 
underpinned the evolution of the links between the different peptides (228). 2043 
Subsequently, the identification of children with loss of function of the POMC 2044 
gene, who have red hair and pale skin, is clear evidence of the importance of 2045 
POMC-derived peptides in skin and hair pigmentation (207). 2046 
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 2047 
Early work detected -MSH and -endorphin, in addition to ACTH, in cultured 2048 
human keratinocytes (343, 431) and human epidermal melanocytes (191, 343, 2049 
362, 363, 414, 431). This suggests that POMC is processed in skin in a manner 2050 
similar to the hypothalamus, rather than the human pituitary. The more 2051 
extensive processing of POMC is substantiated by evidence that PC2 as well as 2052 
PC1/3 is expressed in human and rodent skin (242, 305), in cultured epidermal 2053 
melanocytes (305) and human keratinocytes (333). Interestingly, even human 2054 
dermal fibroblasts express the POMC processing enzymes (344). UV-irradiation 2055 
increases POMC and -MSH-like immunoreactivity (-MSH-LI) in auricular skin 2056 
from mice, but interestingly the -MSH-LI was found to be ACTH (1-8), formed 2057 
by tryptase digestion in the extracellular space. The ACTH (1-8) was shown to 2058 
stimulate melanin production via the MC1R (435). This is an unusual processing 2059 
step which has not been reported in other tissues. 2060 
 2061 
A.  POMC derived peptides and melanogenesis 2062 
 2063 
The action of -MSH was shown dramatically in an in vitro assay using skin from 2064 
frogs, because the -MSH stimulated melanin production and therefore the 2065 
darkening of the skin cells (55, 358). We and others have subsequently used the 2066 
darkening of human melanoma cells, which is visible in the cell pellet, as a 2067 
bioassay to show that although POMC is a precursor of -MSH it is still bioactive 2068 
itself (333).  2069 
 2070 
Early work provided evidence that -MSH stimulated melanogenesis in human 2071 
melanocytes (2, 175), but there was also evidence that the immediate precursor 2072 
of -MSH, i.e. ACTH, could also stimulate melanogenesis (175, 414). This is also 2073 
evidenced by the pigmentation of some patients, particularly those with Nelson’s 2074 
syndrome, who have excessively high concentrations of ACTH in their blood 2075 
(323). However there is always the question as to whether the tumors undergo 2076 
abnormal processing of POMC and produce -MSH. We identified one ectopic 2077 
tumor where the patient had enhanced pigmentation which disappeared after 2078 
removal of the tumor. There was elevated POMC and ACTH in the blood, but no 2079 
excess -MSH (426). This led us to question the relative release of POMC, ACTH 2080 
and -MSH by normal human epidermal keratinocytes, melanocytes and hair 2081 
follicle cells and their relative bioactivity in skin (333). The subtlety lies in the 2082 
concentrations of the respective peptides, as POMC has a low potency so will 2083 
only be bioactive if present at the MC1R at high concentrations. In patients with 2084 
tumors, which are secreting grossly elevated concentrations of POMC, it is likely 2085 
that these precursors of -MSH can cause pigmentation. However, under normal 2086 
conditions the processing of POMC and the regulation of release of the MSH 2087 
peptides allows for paracrine (and maybe autocrine) activity at the melanocytes 2088 
in skin.  2089 
 2090 
It seems plausible that keratinocytes would secrete -MSH related peptides that 2091 
act on cell surface MCRs on melanocytes to stimulate melanogenesis and 2092 
proliferation (186). However it is less clear why epidermal melanocytes secrete 2093 
these peptides. It may be that there is a necessity for an autocrine pathway, or 2094 
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that they act on surrounding keratinocytes and dermal fibroblasts where they 2095 
have a different role, perhaps in differentiation or proliferation. 2096 
 2097 
Both -endorphin and the μ-opiate receptor have been identified in human 2098 
epidermal melanocytes, using immunohistochemistry, again suggesting that 2099 
there is an autocrine mechanism operating in these cells (191). The role of -2100 
endorphin in stimulating melanogenesis, mitogenesis and dendrite outgrowth 2101 
suggests its function is very similar to that of -MSH (191). 2102 
 2103 
B. The skin equivalent of the HPA axis: implications for processing 2104 
(Figure 1) 2105 
 2106 
It was somewhat surprising to learn that all the hormonal components of the 2107 
HPA axis exist in the skin (360, 370). CRH is expressed in the skin (362, 365) and 2108 
can act to stimulate POMC activity and corticosterone synthesis in dermal 2109 
fibroblasts (367-369). Differentiation of human keratinocytes alters expression 2110 
of the components of this skin “HPA axis” indicating marked integration of the 2111 
pathways (428). It has been suggested that the HPA axis represents an 2112 
evolutionary development from the skin “HPA axis” (361). In the skin, the “HPA 2113 
axis” interacts with the innate immune system to protect against pathogens and 2114 
other stressors and then forms an inhibitory loop giving anti-inflammatory 2115 
effects (361). In this model, CRH acts to stimulate POMC gene expression in 2116 
situations where the POMC peptides have an immunoregulatory role (37) and 2117 
where corticosteroids can act to suppress the skin-immune mechanisms. 2118 
 2119 
C. Hair follicles and POMC processing 2120 
 2121 
Hair follicles also produce POMC and process it in a manner analogous to the 2122 
skin (194). This provides the POMC-derived peptides in the hair follicles which 2123 
can modulate pigment formation, activate differentiation and have an 2124 
immunoregulatory role (37, 193). The hair follicles are also regulated by CRH 2125 
(192) and have an equivalent to the HPA axis with synthesis of cortisol (178). 2126 
 2127 
 2128 
D. Assessment of POMC peptides in skin: implications for 2129 
interpretation 2130 
 2131 
The evidence is compelling for the presence of the POMC peptides and the 2132 
importance of their role in skin. However, we must accept that while dispersing 2133 
and culturing the cells allows better quantitation of specific peptides, it may 2134 
mask the true endogenous peptide networks between the cells and cause 2135 
abnormal function. On the other hand, analysis of the peptides in tissues by 2136 
immunohistochemistry is only as good as the knowledge of the specificity of the 2137 
antibodies. We know that antibodies produced with specificity for specific 2138 
peptides such as ACTH, may detect POMC or pro-ACTH as well as ACTH when 2139 
used in immunohistochemistry. Others may be unaware of this, because they do 2140 
not have purified forms of POMC and pro-ACTH to test on their antibodies. 2141 
Another consideration is that some of our knowledge comes from rodents and 2142 
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this might be difficult to extrapolate, for example because they don’t get the same 2143 
exposure to sunlight (361).  2144 
 2145 
The skin can be considered one of the largest organs in the body because of its 2146 
surface area. Therefore, in extrapolating the concentrations of POMC-derived 2147 
peptides in skin to what might appear in blood, some calculations suggest that 2148 
the levels will be so high as to be compatible with causing Cushing’s syndrome. 2149 
Clearly this is not the case and it is thought that the MSH and ACTH peptides are 2150 
degraded locally (346).  2151 
 2152 
 2153 
X.  PITUITARY PROCESSING OF POMC: A KEY FACET IN REGULATION OF 2154 
THE HPA AXIS  2155 
 2156 
The importance of this axis in managing the response to stress is well known. 2157 
However, it is sometimes hard to believe that the intricacy of the production of 2158 
POMC and its processing to ACTH is designed primarily to regulate the release of 2159 
glucocorticoids. In studying the role of ACTH, it is apparent that its effects are 2160 
mainly via glucocorticoids, which act on most tissues in the body to modulate 2161 
homeostatic processes. This is evidenced by the many clinical features that occur 2162 
as a result of glucocorticoid excess as in Cushing’s syndrome. 2163 
 2164 
Secretion of a hormone is almost always regulated by a series of mechanisms to 2165 
tightly control release into the circulation. When there is a hormone precursor 2166 
this adds another layer of complexity. For POMC, the three key stages are 2167 
regulation of (1) the gene (2) the processing enzymes and (3) the secretion from 2168 
cells, as well as some cell-specific post-translational processing, such as 2169 
glycosylation. Unfortunately, we rarely consider all the stages together, so it is 2170 
difficult to understand which of the regulatory mechanisms or which stage in the 2171 
pathway dominates the outcome. 2172 
 2173 
From the perspective of POMC processing, the different stages regulating the 2174 
POMC gene, the enzymes for cleavage of POMC and the secretory vesicle release 2175 
of ACTH have to be coordinated. This is needed so that ACTH is secreted in a 2176 
pulsatile manner, which underpins the circadian rhythm, creating the diurnal 2177 
changes. This “basal” production of ACTH is distinct from the stress-related 2178 
stimulation of ACTH secretion. 2179 
 2180 
A. Ultradian Rhythm and Pulsatile Secretion 2181 
 2182 
The complexity of the rhythms of the HPA axis is still unfolding as new 2183 
techniques give us greater understanding. The pulsatile pattern of secretion of 2184 
ACTH and cortisol has been difficult to assess in humans, because of the stress of 2185 
repetitive blood collection. However the use of automated sampling techniques 2186 
(164) has uncovered the very dynamic nature of these hormones (338). The 2187 
pulses of ACTH occur every 60-90 minutes and have a higher amplitude and 2188 
greater frequency at the circadian peak. Pioneering studies by Stafford Lightman 2189 
and colleagues used mathematical modelling (416) and subsequent in vivo 2190 
experiments to show that the ultradian pattern of ACTH and cortisol derives 2191 
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from a feed forward and a feedback system, involving the pituitary and adrenal 2192 
(415). This rejects the long-held view that pulsatility is caused by a pulse-2193 
generator in a higher centre such as the hypothalamus or hippocampus. Their 2194 
research highlighted the timing of this loop: (1) ACTH secretion, (2) its action on 2195 
the MC2R in the adrenal gland, (3) the de novo synthesis of cortisol and (4) its 2196 
rapid non-genomic negative feedback on ACTH secretion. Given the relatively 2197 
short half-life of ACTH and cortisol, this loop continues with the degradation of 2198 
cortisol, which then removes the glucocorticoid inhibition, so that constant CRH 2199 
stimulation can then increase the ACTH as part of the rising phase of the next 2200 
pulse. The details of this system and the studies that underpin these hypotheses 2201 
are amply described in the review by Russell et al (338). The biological 2202 
significance of the ultradian pulsatility is highlighted by studies showing that 2203 
there are different effects on target genes if glucocorticoids are given constantly 2204 
or in pulses (79, 381). 2205 
 2206 
What is less clear is how POMC processing contributes to this pulsatility, if at all. 2207 
POMC is released into the human circulation (89, 148) and in our study of HPA 2208 
ultradian activity in humans, where POMC was measured in blood, there was no 2209 
evidence for POMC pulsatility (337). Our hypothesis is that POMC is released 2210 
from cells via a constitutive pathway (162, 314) which is separate from the 2211 
regulated release of ACTH. Therefore the rapid glucocorticoid feedback proposed 2212 
for the ultradian pulses could act at secretory vesicles containing ACTH. This 2213 
may occur via cortisol acting on membrane glucocorticoid receptors (389, 395) 2214 
which would provide a non-genomic pathway of feedback inhibition. This 2215 
mechanism is supported by early studies in rodents which showed that a rapid 2216 
glucocorticoid inhibition of ACTH secretion is independent of protein synthesis 2217 
(195) and of POMC processing (115). 2218 
 2219 
B. Circadian rhythm 2220 
 2221 
The concentrations of ACTH in the human circulation show a distinct circadian 2222 
rhythm, with highest levels just before wakening and then a decline throughout 2223 
the day to a nadir between 11pm and 3am. Interestingly, the peak and trough 2224 
values for ACTH differ by two- to three-fold, while those for cortisol can be four- 2225 
to six-fold in healthy individuals. This may be because the adrenal gland has 2226 
sympathetic innervation that is regulated by the PVN or because it has an 2227 
independent clock. Whichever mechanism prevails in the adrenal gland, it 2228 
impacts on the cortisol circadian rhythm to generate the greater magnitude in 2229 
cortisol diurnal rhythm (reviewed in (338)). 2230 
 2231 
This rhythm is under the control of the suprachiasmatic nucleus which 2232 
stimulates release of CRH and AVP from the PVN in the hypothalamus (reviewed 2233 
in (44)). These neuropeptides can stimulate both synthesis of POMC and release 2234 
of ACTH and it is not entirely clear whether one or both mechanisms primarily 2235 
generate the diurnal rhythm. These mechanisms are explored more fully in 2236 
stress-related stimulation of POMC and ACTH below. 2237 
 2238 
 2239 
 2240 
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C. Acute Stress 2241 
 2242 
In the physiological context, stress which stimulates the HPA axis encompasses 2243 
acute illness, haemorrhage, hypoglycaemia and flight from predators requiring 2244 
extreme activation of muscles.  2245 
 2246 
1. CRH stimulation of ACTH release from secretory vesicles (Figure 6) 2247 
 2248 
The classical stressor requires that the hypothalamus releases CRH to cause very 2249 
fast secretion of ACTH into the circulation in order to stimulate cortisol release. 2250 
The mechanism by which CRH stimulates release of secretory vesicles containing 2251 
ACTH involves extracellular calcium influx and release from intracellular pools 2252 
(379). The immediate release of ACTH from secretory vesicles combined with 2253 
the stimulation of POMC synthesis leads to a biphasic response in humans (93). 2254 
It is difficult to assess the immediate release of ACTH and POMC after CRH in 2255 
normal subjects, but this has been documented in patients who undergo petrosal 2256 
sinus sampling for a suspected ACTH-secreting pituitary tumor. After CRH 2257 
stimulation, ACTH released into the petrosal sinus capillaries can be measured 2258 
within minutes. The stimulated release usually results in a peak of ACTH within 2259 
5-15 minutes. POMC release from the pituitary can be detected but it does not 2260 
mimic the marked increase in ACTH (Figure 6)(148). This has led us to 2261 
hypothesize that POMC is released from the corticotropes via a different 2262 
mechanism to ACTH. It could be that in the steady state when there are sufficient 2263 
ACTH vesicles, the excess POMC exits the cells by a constitutive pathway 2264 
representing an “overflow” mechanism (384). This is substantiated in normal 2265 
subjects where CRH caused an increase in circulating ACTH but no change in 2266 
ACTH precursors (337). 2267 
 2268 
Figure 6: Regulatory processes for the secretion of POMC and its peptides 2269 
 2270 
2. CRH stimulation of the POMC gene in the anterior pituitary (Figure 6) 2271 
 2272 
It has long been recognized that the binding of CRH to a corticotropic cell results 2273 
in CRH activation of POMC transcription (142), presumably to replenish stores of 2274 
ACTH peptide in the secretory vesicles. It is possible that stimulation of the 2275 
POMC gene involves the same intermediary factors which act on the channels to 2276 
cause ACTH secretion. CRH receptor activation seems to have effects on a 2277 
number of pathways (overview in (162); reviewed in detail in (104)). Early work 2278 
defined the effect of CRH on cAMP pathways both in vitro and in vivo (231). CRH 2279 
is known to increase cAMP, calcium and MAPK in POMC expressing cells (204, 2280 
236). There is also evidence that CRH stimulates transcription of JunB, c-fos, and 2281 
FosB, transcription factors that bind to the AP-1 transcription factor binding site 2282 
in exon 1 of the POMC promoter, activating POMC transcription (13, 42).   2283 
 2284 
More recent data has delineated a MAPK pathway which activates nuclear 2285 
receptors related to NGFI-B (Nur77) and these bind to a Nur response element in 2286 
a regulatory element at -404bp of the rat POMC promoter (reviewed in (104)). 2287 
MAPK signaling enables the Nur factors to bind SRC co-activators which enhance 2288 
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POMC transcription. CRH signaling also activates Tif1 which is synergistic with 2289 
SRC2 action (321).    2290 
 2291 
3. CRH regulation of processing 2292 
 2293 
There is very little evidence in the literature to suggest that that the processing 2294 
of POMC to ACTH is regulated or that the pro-hormone convertase, PC1, is 2295 
stimulated by CRH. However there is always the caveat that “this is an 2296 
experiment waiting to be done”. 2297 
 2298 
4. Stimulation of ACTH by other factors acting on CRH 2299 
 2300 
Many other factors have been reported to stimulate release of ACTH, such as 2301 
catecholamines, angiotensin II, interleukins (24, 341), ghrelin, vasoactive 2302 
intestinal polypeptide (VIP) (271), serotonin and oxytocin. However, they mostly 2303 
act via CRH and there is little evidence for direct effects on POMC gene 2304 
expression. Opioid peptides also affect the HPA axis, but in differing ways 2305 
depending on the species studied and whether the actions are acute or chronic.  2306 
It has also been suggested that opioids are acting at the level of CRH release 2307 
(396, 402). 2308 
 2309 
5. Stimulation of ACTH by argenine vasopressin 2310 
 2311 
Early work outlined the potentiation of CRH-stimulated secretion of POMC-2312 
derived peptides by arginine vasopressin (AVP) (408) and this is often stated as 2313 
a key regulatory role in the HPA axis. There seems to be a clear distinction, 2314 
because while AVP can synergize with CRH to stimulate ACTH release, it does not 2315 
appear to act on transcription of the gene. In fact, AVP alone decreases levels of 2316 
the POMC primary transcript and does not act in a synergistic manner with CRH 2317 
on POMC gene expression in rat anterior pituitary primary cultures (219). 2318 
 2319 
6. Other factors which stimulate POMC gene expression 2320 
 2321 
Given the physiological importance of the interactions between the immune 2322 
system and the HPA axis, it is not surprising that leukemia inhibitory factor (LIF), 2323 
which is a pro-inflammatory cytokine, activates POMC gene expression (41, 324, 2324 
325). LIF binding activates the Jak-STAT pathway and there is a STAT binding 2325 
site in the proximal POMC promoter close to the Nur response element (262). 2326 
This suggests that the HPA axis role in toning-down the cytokine response 2327 
requires increased POMC gene expression, which may provide a greater or 2328 
prolonged effect on glucocorticoid release compared to the stress response that 2329 
is set up to deliver fast release of ACTH into the circulation. 2330 
 2331 
D.  Feedback inhibition of the HPA axis by glucocorticoids (Figure 6) 2332 
 2333 
The classical hormonal axes involving the hypothalamus and pituitary have the 2334 
ability to generate a loop, whereby stimulation at several stages leads to a 2335 
hormone, which feeds back and switches off the cascade. Glucocorticoid 2336 
inhibition of the HPA axis is one of the best examples of this tightly regulated 2337 
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feedback system. Stress activation of the HPA axis must incorporate a 2338 
mechanism to switch off glucocorticoid release, which if unrestrained would lead 2339 
to not only prolonged immune suppression, but also a very adverse profile of 2340 
effects in many tissues. The inhibition by glucocorticoids is complex and some 2341 
reports highlight the importance of regulation at the level of CRH in the 2342 
hypothalamus, while others suggest that inhibition of POMC gene expression and 2343 
ACTH release are the critical components (96). There have been some elegant 2344 
studies addressing the issues of the effects of acute glucocorticoid feedback on 2345 
stress-related activation of the HPA axis, considering the timing of glucocorticoid 2346 
feedback particularly in in vivo paradigms (90, 282).  2347 
 2348 
1. Glucocorticoid inhibition of ACTH release 2349 
 2350 
After a stressor activates the HPA axis, the surge in cortisol feeds back at the 2351 
pituitary and inhibits ACTH release. This is rapid and is thought to be a non-2352 
genomic mechanism, with glucocorticoids acting on secretory vesicle release 2353 
(96). Early research suggested that glucocorticoids inhibit the calcium signaling, 2354 
which triggers release of ACTH from the plasma membrane (8). 2355 
 2356 
Another mechanism involves Annexin 1 (ANXA1) which was originally identified 2357 
as an anti-inflammatory protein. ANXA1 is released from folliculostellate cells in 2358 
the pituitary in response to glucocorticoid stimulation and this causes 2359 
translocation of ANXA1 to the outside of the cell by a mechanism which doesn’t 2360 
involve exocytosis. ANXA1 then inhibits CRH-stimulated ACTH secretion (43). 2361 
Given the steps involved, it would seem that this feedback would take longer to 2362 
have its effects on ACTH. 2363 
 2364 
2. Glucocorticoid inhibition of the POMC gene 2365 
 2366 
Over the longer term, glucocorticoids can inhibit POMC gene expression. They 2367 
access the pituitary because it is outside the blood-brain barrier and then diffuse 2368 
into the corticotropes to bind the intracellular glucocorticoid receptors (GRs). 2369 
These receptors are part of the nuclear hormone receptor family and on binding 2370 
of ligand they are released from heat shock proteins in the cytoplasm, allowing 2371 
them to translocate to the nucleus. There they bind to negative glucocorticoid 2372 
response elements (nGREs) in the promoter region of the POMC gene to inhibit 2373 
transcription. The regulation of the POMC gene by glucocorticoids was first 2374 
explored in the 1980s (33, 141). A region necessary for repression was identified 2375 
at -77 to -50 relative to the transcription start site of POMC (107, 108) and a 2376 
second site between -480 and -320 was subsequently mapped (327). This site 2377 
involves the NurRE at -395 bps from the start site (307, 308). GRs interact with 2378 
Nur factors by protein/protein interactions and this requires BRG1, part of the 2379 
SW1/SNF remodeling complex, and HDAC2, a histone deacetylase (31). Both 2380 
these sites are necessary to effect transcriptional inhibition. What is unusual 2381 
about the nGRE at -63bp in the rat Pomc promoter is that it binds a GR 2382 
homodimer as found in positive GREs but then a GR monomer binds to the 2383 
opposite side of the helix in the promoter (106).  2384 
 2385 
 2386 
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3. Glucocorticoid inhibition of POMC processing enzymes 2387 
 2388 
It seems logical that the regulation of expression of the processing enzyme that 2389 
cleaves POMC i.e. PC1/3 parallels that of POMC in corticotropes. Indeed studies 2390 
in rats showed that adrenalectomy increased the mRNA levels of PC1/3 and that 2391 
dexamethasone treatment of the adrenalectomized animals reversed this. This 2392 
suggests that endogenous glucocorticoids would inhibit the expression of the 2393 
processing enzymes in the corticotropic cells (101). 2394 
 2395 
E.  Stress recovery mechanisms: the role of Cannabinoids 2396 
 2397 
The endocannabinoids are involved in stress recovery mechanisms and 2398 
homeostasis, therefore, it is not surprising that they have effects on the HPA axis. 2399 
However, the literature suggests that the effects are very dependent on the 2400 
context. Several studies have reported that cannabinoid agonists increase 2401 
circulating ACTH in animal models (reviewed in (288)). There is some 2402 
suggestion that these agonists act by increasing CRH although, the cannabinoid 2403 
receptor CB1, is present on ACTH secreting cells (289), indicating that 2404 
cannabinoids are having a direct effect at the level of the pituitary. Interestingly, 2405 
mice with knockdown of CB1 have increased levels of corticosterone and a 2406 
generalized upregulation of the HPA axis (84), which would indicate that 2407 
endocannabinoids also have the potential to inhibit the HPA axis. This fits with 2408 
the proposal that endocannabinoids can inhibit stress-induced HPA axis 2409 
activation and therefore may be of value in treatment of anxiety-related 2410 
disorders (299). 2411 
 2412 
 2413 
XI.  POMC PROCESSING BY TUMORS 2414 
 2415 
Cushing’s Syndrome is defined by excess cortisol secretion which can be caused 2416 
by pituitary tumors that secrete ACTH or non-pituitary or ectopic tumors, which 2417 
we believe secrete predominantly ACTH precursors (423) (Figure 7). The latter 2418 
is referred to as ectopic ACTH syndrome but we have suggested it should be 2419 
renamed ectopic ACTH precursor syndrome (385). The tumors are often small 2420 
cell lung carcinomas (SCLC) but can also be pancreatic, thyroid, or carcinoid 2421 
tumors or phaeochromocytomas. 2422 
 2423 
Much of what we know now about POMC as the precursor of ACTH arose from 2424 
observations of tumors producing “abnormal” ACTH molecules. This was often 2425 
investigated because the patient would have symptoms of Cushing’s syndrome 2426 
which were suggestive of high ACTH concentrations in the patient’s blood, but 2427 
the results would be inconsistent. We now know this is most often because some 2428 
of these tumors were producing ACTH precursors. These precursors seem to 2429 
have a lower bioactivity, as only relatively high concentrations stimulate cortisol 2430 
production and are associated with clinical symptoms of cortisol excess. In 2431 
addition, although ACTH assays used in the clinic have some cross reactivity for 2432 
ACTH precursors, they only measure approximately 2% of the total precursors 2433 
(255). This can result in a “normal” ACTH and only slightly elevated cortisol but 2434 
because there is no diurnal rhythm, this change in the HPA axis can give 2435 
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symptoms of Cushing’s syndrome. With more specific assays and more sensitive 2436 
imaging techniques it is now easier to get a diagnosis, although there are still 2437 
some patients who present with a confusing set of diagnostic results, indicating 2438 
we still have more to discover.  2439 
 2440 
We developed a two-site immunoradiometric assay for ACTH precursors in 1988 2441 
(89), using a pair of monoclonal antibodies. One antibody binds to the ACTH 2442 
region of POMC and the other to the -MSH region (see section XII). Binding of 2443 
both antibodies is required to generate a signal and this only occurs when POMC 2444 
or pro-ACTH are present. Importantly, this assay for ACTH precursors does not 2445 
detect ACTH. In contrast, an assay for ACTH will always recognize ACTH 2446 
precursors to some degree, because the ACTH sequence is present in both pro-2447 
ACTH and POMC. This is very important in diagnostic ACTH assays, as they need 2448 
to identify any peptides with ACTH-like activity. However as the antibodies 2449 
cross-react 100% with ACTH but only <5% with POMC, (255, 385) this can lead 2450 
to the discrepancies described above. 2451 
 2452 
A. ACTH precursor secretion in ectopic ACTH syndrome 2453 
 2454 
High molecular weight forms of ACTH were first found in an ectopic tumor 2455 
extract using chromatographic separation and then radioimmunoassay (433). 2456 
These high molecular weight forms were subsequently found in patients’ blood 2457 
(159, 322), but it required large volumes of plasma for the procedure and took 2458 
several days, so it was not a suitable approach to use routinely. Most reported 2459 
chromatograms show a major elution peak at the position for POMC and a 2460 
shoulder to the peak, suggesting some pro-ACTH, but the resolution was not 2461 
usually specific enough to determine relative amounts.  2462 
 2463 
Figure 7: ACTH precursor secretion in ectopic ACTH syndrome 2464 
 2465 
Quantifying ACTH-precursors, using the two-site immunoradiometric assay, 2466 
revealed that most of the patients with ectopic ACTH syndrome had elevated 2467 
circulating concentrations (385) (Figure 8). It is very difficult to prove whether 2468 
the ACTH precursors or bonafide ACTH cause the clinical symptoms in these 2469 
patients. Low concentrations of ACTH (around 1.0 pmol/L) secreted 2470 
continuously from tumors, and therefore not subject to a diurnal rhythm, are 2471 
thought to be able to cause elevated cortisol, which can result in Cushing’s 2472 
syndrome. We did not detect ACTH in the chromatographed plasma from a 2473 
patient with ectopic ACTH syndrome, where we measured high levels of ACTH 2474 
precursors. This suggests that ACTH precursors were bioactive in this case, but 2475 
we cannot completely rule out the possibility that the lack of detection of ACTH 2476 
may be due to sensitivity limitations of the chromatography (385). 2477 
 2478 
Carcinoid tumors can also secrete ACTH precursors and produce features of the 2479 
ectopic ACTH syndrome, even though they are often much smaller tumors (423). 2480 
However other work using an assay specific for POMC, which did not detect pro-2481 
ACTH, suggested POMC was not present in the bronchial carcinoids they studied 2482 
(319). To add to the confusion, this group detected CLIP (the C-terminal 2483 
fragment of ACTH) in four carcinoid tumor extracts (413). Unfortunately the 2484 
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concentrations of precursors, ACTH and CLIP were not measured in the same 2485 
patients in any of the studies and it is not clear if the antibody to CLIP recognized 2486 
POMC. If CLIP is present in a selection of tumors, this suggests that these tumors 2487 
have the processing enzymes, PC1/3 and PC2, to cleave POMC to these smaller 2488 
fragments. Indeed PC2 has been detected in the majority of carcinoid tumors 2489 
studied (347). However, more recently, it has become clear that patients with 2490 
less aggressive Cushing’s syndrome caused by carcinoid tumors have elevated 2491 
ACTH precursors (285) (Figure 8). 2492 
 2493 
Figure 8: Concentrations of ACTH precursors in different patient groups 2494 
 2495 
B.  POMC processing in pituitary microadenomas 2496 
 2497 
Patients with small pituitary microadenomas causing Cushing’s disease process 2498 
POMC to ACTH, seemingly in a similar way to normal subjects. Therefore, while 2499 
ACTH precursors are detectable (as they are in normal subjects), the 2500 
concentrations range from low normal to approximately 100pmol/L (278). 2501 
However patients with ectopic tumors causing Cushing’s syndrome have ACTH 2502 
precursors in the range 100-20,000 pmol/L (425). This gives virtually 100% 2503 
discrimination between patients with pituitary dependent Cushing’s syndrome 2504 
and ectopic ACTH syndrome (Figure 8). 2505 
 2506 
In addition to ACTH, the precursors can be detected in samples taken from the 2507 
inferior petrosal sinuses, draining the pituitary, in patients with pituitary 2508 
microadenomas. However, when CRH is given as part of this procedure, while the 2509 
ACTH concentrations increase, the ACTH precursors do not seem to respond to 2510 
CRH to the same degree, suggesting that the mechanisms for regulation of 2511 
release of ACTH and ACTH precursors may differ (148). 2512 
 2513 
C. POMC processing in large invasive pituitary tumors 2514 
 2515 
There is a small subset of patients who have much larger tumors, which tend to 2516 
be invasive (11), and they may present with vague symptoms of Cushing’s 2517 
syndrome and abnormally low ACTH results considering the clinical features. 2518 
Investigating a small group of these tumors we found that they also have high 2519 
concentrations of ACTH precursors in the blood (150) and a POMC specific assay 2520 
has identified elevated POMC in 7/8 patients (319).  2521 
 2522 
There are also “silent” tumors in patients who do not appear to have elevated 2523 
ACTH in the circulation, but their tumors stain positively for “ACTH”. In cases we 2524 
have studied, this is because the tumors produce ACTH precursors, which can be 2525 
detected by the ACTH antibody used in immunohistochemistry. If the tumors 2526 
have not been completely removed at surgery and there is recurrence, the ACTH 2527 
precursors can be detected in the circulation. 2528 
 2529 
There is also some evidence for large invasive pituitary adenomas producing -2530 
MSH and most of these were immunopositive for PC2 (176). Unfortunately, 2531 
ACTH precursors were not measured in these patients and so it is not possible to 2532 
speculate on the molar ratios of the POMC peptides produced by these tumors. 2533 
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 2534 
D. POMC processing in Nelson’s syndrome 2535 
 2536 
Nelson’s syndrome is relatively rare, but has highlighted some interesting 2537 
aspects of POMC processing which are still not fully understood. Nelson’s 2538 
syndrome occurs after bilateral adrenalectomy which is used as a means of 2539 
treating some cases of Cushing’s syndrome. Subsequently, a pituitary adenoma, 2540 
usually not detected as the cause of the Cushing’s syndrome, then expands and 2541 
secretes high concentrations of ACTH, often resulting in pigmentation.  2542 
 2543 
These pituitary tumors are often invasive and this led us to investigate whether 2544 
they secreted ACTH precursors in a similar fashion to the group of large invasive 2545 
pituitary tumors we had studied previously (150). The ACTH precursors were 2546 
elevated in 11 of the 24 patients (median 97.5pmol/L, range 26 to 647pmol/L), 2547 
compared to untreated Cushing’s disease where the range was 9-104pmol/L 2548 
(Figure 7) However, the processing of POMC to ACTH appeared to be enhanced 2549 
as evidenced by the ratio of precursors to ACTH (323). This seemed unusual, but 2550 
suggests that the lack of endogenous cortisol and the presence of oral 2551 
hydrocortisone for only part of the 24h period may have affected the processing 2552 
of POMC to ACTH. 2553 
 2554 
E. Processing of POMC in tumor cells 2555 
 2556 
There is ample evidence of POMC production and secretion by pituitary and 2557 
ectopic tumors (276, 278, 285, 319). Why this occurs is still a matter of 2558 
speculation (423). The processing pathway to produce ACTH is complex and 2559 
requires the presence of PC1/3 and mature secretory vesicles, to provide the 2560 
correct calcium and pH optimal for the processing. Therefore it seems 2561 
reasonable to predict that some tumors (particularly non-pituitary tumors) may 2562 
not have differentiated sufficiently to generate this pathway. However, these 2563 
ectopic tumors are often characterized by large dense core secretory vesicles, 2564 
which is the location for processing precursor hormones. It may be that these 2565 
tumors are less differentiated and not able to synthesize PC1/3. This is 2566 
supported by a study of 13 SCLC cell lines which had restricted expression of 2567 
PC1/3 (87). We have also found high levels of precursors and undetectable ACTH 2568 
in SCLC cell lines (88, 385). The fact that large invasive pituitary tumors can 2569 
produce ACTH precursors at higher concentrations than ACTH also supports the 2570 
suggestion that aggressive, less differentiated tumors may not fully process 2571 
POMC to ACTH. However, the increased processing in those pituitary tumors 2572 
associated with Nelson’s syndrome suggests that the lack of “natural” 2573 
glucocorticoid feedback inhibition may be influencing processing.  2574 
 2575 
 2576 
XII. MEASUREMENT OF POMC DERIVED PEPTIDES – WHAT ARE WE 2577 
REALLY MEASURING? 2578 
 2579 
Measurement of ACTH initially involved a bioassay using rat adrenal cells that 2580 
secreted corticosterone. This was very sensitive and could detect circulating 2581 
ACTH but was also very variable due to the unpredictability in responsiveness of 2582 
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different adrenal preparations (61). Subsequently a few research groups, largely 2583 
based within hospital laboratories, began to produce polyclonal antisera and 2584 
develop immunoassays to measure ACTH. With these assays it was possible to 2585 
identify discordance between the clinical features in some patients with tumors 2586 
and the low levels of ACTH detected. This led to the concept that some tumors 2587 
might be producing abnormal molecules with ACTH activity (see section XI 2588 
above). This set the context for the development of methods to accurately assess 2589 
the POMC peptides. 2590 
 2591 
A. The value of pulse-chase analysis 2592 
 2593 
In trying to understand the relevance of pro-hormone processing, we rely 2594 
heavily on the methodology used to address the questions. Without pulse-chase 2595 
analysis it may have been many years before pro-insulin was discovered. 2596 
Similarly much of the early work on POMC, as the precursor of ACTH, relied on 2597 
pulse-chase analysis of POMC peptides from the AtT20 mouse pituitary adenoma 2598 
cell line (119, 232). These cells were incubated with a radiolabeled amino acid 2599 
and then after a set time “chased” with unlabeled amino acid. This provides a 2600 
profile of labeled peptides over time. Antibodies are used to identify and 2601 
concentrate the specific peptides and then SDS-gel electrophoresis determines 2602 
the size of the peptides. This is a dynamic process studying the timing of the 2603 
appearance and disappearance of the labeled peptides. The information on the 2604 
relative amounts of each of the peptides in the processing pathway depends on 2605 
the ability of the antibody to recognize a particular epitope in ACTH, pro-ACTH 2606 
and POMC. From immunoassay data, we are aware that antibodies may 2607 
recognize ACTH to a greater degree than the precursors. There is also the 2608 
possibility that the different conditions used in immunoprecipitation can affect 2609 
the relative recognition of the three peptides, so it is important to consider 2610 
antibody specificity for the different peptides under these conditions, in order to 2611 
interpret the data. 2612 
 2613 
Much of the data proving that ACTH and -endorphin come from POMC was 2614 
derived from extensive and very methodical pulse-chase analysis (119). This 2615 
biochemical analysis preceded the identification of the gene structure and 2616 
provided invaluable information on POMC processing. 2617 
 2618 
B. Immunoassays for ACTH 2619 
 2620 
The clinical need for measurement of ACTH became apparent with identification 2621 
of tumors secreting ACTH as a cause of Cushing’s syndrome (281, 434). Many 2622 
immunoassays for clinically relevant hormones were developed shortly after the 2623 
initial immunoassay for insulin had been described. However, development of 2624 
polyclonal antisera to ACTH proved difficult, as the ACTH peptide is not very 2625 
immunogenic. In addition, there were problems with radiolabeling ACTH for the 2626 
radioimmunoassays, as it was very labile. At this time, extraction of ACTH from 2627 
plasma was necessary to improve the detection of low normal concentrations 2628 
and laboratories used the knowledge that ACTH sticks to ground glass or silica 2629 
for this purpose. This process concentrated the ACTH, to allow for the lack of 2630 
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sensitivity of the immunoassays, while at the same time removing the plasma, 2631 
which interfered in many of the immunoassays.  2632 
 2633 
The advent of a two-site immunoradiometric assay based on polyclonal 2634 
antibodies to ACTH provided significant advantages (171). However, the ability 2635 
to generate monoclonal antibodies to ACTH (424) (Figure 9) enabled the 2636 
characterization of a monoclonal antibody-based immunoradiometric assay 2637 
(427). Having hybrid cell lines secreting large quantities of monoclonal 2638 
antibodies led the way for development of commercial diagnostic assays, which 2639 
opened up ACTH measurement to a much wider clinical community. However, it 2640 
was also known that some tumors produced high molecular weight forms of 2641 
ACTH, while other tumors were thought to produce ACTH fragments. The 2642 
immunoradiometric assays were considered very specific for ACTH (135) and 2643 
the assay based on the paper by Hodgkinson et al (171) was found not to detect 2644 
the “big ACTH” produced by tumors (139). Similarly ACTH fragments not 2645 
detected in the immunoradiometric assays can cause problems (317). In essence, 2646 
it is important that the ACTH assays do detect ACTH precursors or fragments 2647 
produced by tumors, but only if the precursors or fragments are bioactive and 2648 
responsible for the clinical symptoms. 2649 
 2650 
C. Immunometric assays for ACTH precursors (Figure 9) 2651 
 2652 
Many immunoassays for ACTH can also detect the high molecular weight forms 2653 
of ACTH, such as POMC and pro-ACTH. In this instance, the antibodies which 2654 
bind ACTH can also recognize this sequence in POMC. However, the antibody 2655 
may not recognize the ACTH sequence to the same degree in the larger precursor 2656 
molecule. Therefore, the ACTH assay may underestimate the concentration of 2657 
POMC, because of its low cross-reactivity with the antibodies. This has been 2658 
accentuated in the two-site immunometric assays for ACTH with many of them 2659 
only detecting 2% of the POMC precursors present (255).  2660 
 2661 
Figure 9: Monoclonal antibody based assays to POMC derived peptides 2662 
 2663 
The development of an immunometric assay for POMC and pro-ACTH (89), 2664 
provided the opportunity to specifically quantitate these precursors without the 2665 
problem of trying to accurately measure them in the ACTH assay. In the 2666 
precursor assay we developed, one antibody detects an epitope in ACTH and the 2667 
other antibody detects an epitope in -MSH. Since both antibodies are required 2668 
to generate a signal, only peptides containing both epitopes (i.e. POMC and pro-2669 
ACTH) are measured. Therefore the smaller peptides, including ACTH, are not 2670 
recognized by the assay (Figure 9). The second factor which made this assay 2671 
possible was that we were able to use culture medium from a pituitary tumor 2672 
growing in vitro as a source of POMC and subsequently to prepare standards by 2673 
purifying POMC from a human small cell lung cancer cell line (89).    2674 
 2675 
This assay for ACTH precursors confirmed the early work on high molecular 2676 
weight ACTH, ie POMC and pro-ACTH, in tumors. It has enabled analysis of much 2677 
larger numbers of patients and proved that high levels of ACTH precursors can 2678 
be found in the blood of patients with ectopic ACTH syndrome (385). The greater 2679 
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sensitivity of this approach allows ACTH precursors to be measured directly, 2680 
without the need for chromatography, greatly enhancing our understanding of 2681 
the processing in ACTH-related disorders (150, 278, 285, 323). Another 2682 
immunometric assay for POMC based on antibodies to epitopes in ACTH and -2683 
endorphin showed greater heterogeneity, but still detected elevated POMC levels 2684 
associated with more aggressive tumors in patients with ACTH-related disorders 2685 
(319).  2686 
 2687 
The immunometric assay technology enables lower concentrations to be 2688 
detected. This has made it possible to measure POMC in plasma (148, 285, 337) 2689 
and in CSF (286, 403) from normal subjects. 2690 
 2691 
D. Immunometric assays for -LPH and -endorphin 2692 
 2693 
By developing two-site assays similar to those for ACTH and ACTH precursors, it 2694 
has been possible to generate assays that distinguish -LPH and -endorphin 2695 
(149). This provided evidence that there is very little -endorphin in the human 2696 
circulation and its precursor, -LPH, is more prevalent. It is likely that some of 2697 
the original radioimmunoassays for -endorphin actually detected its precursor, 2698 
-LPH. 2699 
 2700 
E. Which POMC peptide are you measuring by immunohistochemistry? 2701 
 2702 
Accurate detection of POMC and the smaller melanocortin peptides in tissues by 2703 
immunohistochemistry remains complex. Antibodies raised to -MSH, for 2704 
example, may be wholly specific for that peptide or may recognize the amino 2705 
acid sequence in ACTH, pro-ACTH and/or POMC. It is challenging to use single 2706 
antibodies in immunohistochemistry to detect fully processed peptides as they 2707 
may be identifying the larger POMC precursor. This is made more relevant as the 2708 
precursors are thought to be less biologically active and therefore a tissue or 2709 
tumor may have a bioactive smaller peptide or a less bioactive precursor. The 2710 
specificity of the antibody can be assessed by competing with increasing 2711 
concentrations of the precursors, but these are not generally available. 2712 
 2713 
We have an antibody that recognizes the C-terminal of ACTH and therefore 2714 
detects ACTH and pro-ACTH but not POMC. This has been proven in 2715 
immunoassays and has also been used in immunohistochemistry to show that a 2716 
tumor was producing POMC but not ACTH, which helped explain the clinical 2717 
symptoms in relation to the POMC derived peptides in the circulation (146). 2718 
 2719 
 2720 
XVIII.  BIOACTIVITY OF POMC AND DERIVED PEPTIDES 2721 
 2722 
A. Bioactivity of ACTH Precursors 2723 
 2724 
The perceived role of a precursor in relation to its peptide products would 2725 
suggest that the precursor is not biologically active and that the reason for 2726 
regulating the processing steps is to provide bioactive end products. The 2727 
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situation is slightly more complex with POMC and ACTH and much less is known 2728 
about other POMC derived peptides such as -MSH and -endorphin. 2729 
 2730 
The relative bioactivity of POMC and ACTH was addressed in the 1970’s using 2731 
POMC (then called pro-ACTH/endorphin) isolated primarily from AtT20 mouse 2732 
pituitary adenoma cells. The peptides were purified by gel chromatography and 2733 
SDS gel electrophoresis, then measured using an ACTH radioimmunoassay and 2734 
tested on rat adrenocortical cells, which produced corticosterone as the evidence 2735 
of bioactivity. Initially this approach provided proof of the relative position of the 2736 
different peptides within the POMC precursor, in that it had not previously been 2737 
known that N-POMC was N-terminal to ACTH and ACTH was N-terminal to -2738 
LPH. These studies also showed that POMC and pro-ACTH were two orders of 2739 
magnitude less bioactive than ACTH (1-39) (145). This data does depend on the 2740 
accuracy of the quantitation of the precursor peptides used in the bioassay. It is 2741 
clear that this was recognized as an issue at that stage because Eipper and Mains 2742 
(119) commented “it has been known for some time that radioimmunoassays for 2743 
ACTH may only detect a few percent of the high molecular weight forms”. They 2744 
indicate that this will bias the ratio of bioactive to immunoactive peptide 2745 
measured. 2746 
 2747 
This careful study of bioactivity provided evidence that the precursors of ACTH 2748 
were able to stimulate corticosterone production without a time lag, indicating 2749 
that it did not require proteolysis for the precursors to act at the MCRs on the rat 2750 
adrenocortical cell membranes (145). Nevertheless, much higher concentrations 2751 
of precursors were needed to have an effect. 2752 
 2753 
This work underpinned the concept that POMC is a precursor with relatively low 2754 
biological activity (119, 276). However, pro-ACTH has 8-33% the potency of 2755 
ACTH in a cytochemical bioassay (322), suggesting that having the ACTH 2756 
sequence at the C-terminal end of this precursor makes it more bioactive than 2757 
when ACTH is flanked at both ends by other peptides. This makes the 2758 
interpretation of which peptides are present in the circulation and how they are 2759 
measured very relevant (423). 2760 
 2761 
To analyze bioactivity, research groups primarily used tumor extracts as the 2762 
source of POMC. The “big” ACTH in human non-pituitary tumor extracts was 2763 
found to be relatively biologically inactive (168) or had less than 4% bioactivity 2764 
(147). It was also shown that trypsin can convert the “big” ACTH peptide to a 2765 
biologically active ACTH (147). Other groups isolated “big” ACTH, from a human 2766 
pituitary tumor, and found it to have 30% of the bioactivity of ACTH (118, 206) , 2767 
suggesting that the peptides isolated may have been a mixture of POMC and pro-2768 
ACTH. 2769 
 2770 
Using the ACTH precursor assay to quantitate POMC and pro-ACTH purified from 2771 
the plasma of a patient with an ectopic tumor, provided evidence that the ACTH 2772 
precursors, rather than ACTH, might be responsible for the clinical symptoms 2773 
(385). It was suggested that although they have low bioactivity, they may still act 2774 
with low potency if they are present in the circulation at very high 2775 
concentrations. Another option is that the high concentrations of ACTH 2776 
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precursors are cleaved at the adrenal cells and, even if this cleavage is very 2777 
inefficient, the concentrations of ACTH generated may be sufficient to stimulate 2778 
excess cortisol, especially at the diurnal nadir.  2779 
 2780 
B. Relative bioactivity of -MSH and its precursors ACTH and POMC 2781 
 2782 
For some reason, very little has been done to consider if the precursors of -MSH 2783 
act in the hypothalamus at MC4R or in the skin at MC1R, although we have tried 2784 
to address this. ACTH is able to act at the MC4R, found in the hypothalamus, with 2785 
a similar potency to -MSH (311). POMC is less bioactive, but may still act if 2786 
present at 100 fold higher concentrations and it is intriguing that this level of 2787 
excess is found in the CSF (287, 403). Similarly, ACTH can act at the MC1R found 2788 
in skin with a similar potency to -MSH (333) where again POMC has low 2789 
bioactivity. Therefore, it is important to understand the relative concentrations 2790 
of the precursors as well as their derived peptides in the vicinity of their 2791 
receptors, particularly if acetylation of -MSH is so tightly regulated (156). 2792 
 2793 
 2794 
XIV. CONUNDRUMS AND FUTURE PERSEPECTIVES 2795 
 2796 
The wealth of data presented in this review is testament to the essential roles 2797 
played by POMC-derived peptides in a vast array of tissues and in many diverse 2798 
physiological systems. In many research arenas there is an inevitable tendency 2799 
to focus in on one particular tissue or cell type. Hopefully this review will 2800 
encourage those working, for example, on hypothalamic signaling to also look at 2801 
the complexity of regulation of POMC processing in the skin and vice versa. Only 2802 
by grappling with the subtlety of homeostatic control mechanisms in all relevant 2803 
tissues, can one appreciate the full power of hormone processing vital for 2804 
physiological processes in many biological systems. 2805 
 2806 
In presenting POMC as the archetypal polypeptide precursor, this review has 2807 
addressed processing to generate the smaller peptide fragments at the molecular 2808 
and cellular level. Understanding the processing steps responsible for cleavage of 2809 
POMC and how they differ in certain tissues, sets the context for recognition of 2810 
how mutations lead to such widespread phenotypes in both humans and mice. 2811 
By considering the processing pathway from the TGN to the cell surface, it is 2812 
possible to address questions about how the regulated secretion of ACTH from 2813 
the pituitary occurs so rapidly in response to stress. This is obviously necessary 2814 
in order to stimulate the glucocorticoid concentrations needed for metabolic 2815 
support in the “fight and flight” mechanisms. However, a complete 2816 
understanding of the regulation of the POMC gene in the hypothalamus remains 2817 
more elusive and much less is known about how processing in the secretory 2818 
granules proceeds within relevant hypothalamic neurons. For example, this 2819 
review has provided evidence for regulation of the many enzymes involved in 2820 
generating bioactive -MSH. Because this needs to occur in secretory vesicles 2821 
rather than in the extra-cellular space, it remains to be determined how the 2822 
length of the neuronal projections affects the various stages in acetylation and 2823 
amidation of -MSH.  2824 
 2825 
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Our gathering of evidence for the complexity of POMC processing in all of the 2826 
many tissues where it is expressed has again raised issues about which POMC 2827 
peptides have biological activity and highlighted continuing uncertainty of the 2828 
unique versus overlapping roles of melanocortins. Where a block in the post-2829 
translational mechanisms affects processing and there is a build up of POMC 2830 
precursors, it is important to understand if the biological activity of these 2831 
precursors is contributing, even in part, to changes in physiological processes 2832 
normally ascribed to the smaller, more highly processed peptides like ACTH, -2833 
MSH or -endorphin. This phenomenon has been accepted for many years by 2834 
endocrinologists studying tumors secreting ACTH-related peptides, but the more 2835 
recent identification of children with mutations in POMC or with mutations in the 2836 
enzymes involved in processing POMC, has shone a light into another biological 2837 
theatre in which precursors could have important actions. 2838 
  2839 
One of the major stumbling blocks to a more complete knowledge of which 2840 
POMC peptides are involved in particular physiological processes, is the problem 2841 
of attempting to measure one peptide specifically without inadvertently also 2842 
measuring its larger precursor or a smaller peptide derived from it. This is a 2843 
particular issue for immunoassays that rely on the specificity of the antibody. For 2844 
example, in the case of ACTH assays their recognition of POMC or pro-ACTH is 2845 
rarely understood. There is now evidence that most immunometric assays for 2846 
ACTH only detect about 2% of the precursors present. If the aim is to use this 2847 
approach to measure POMC and pro-ACTH, then it massively underestimates 2848 
their true concentrations. This has undoubtedly hampered the understanding of 2849 
some cell-based studies. 2850 
 2851 
The sensitivity of the detection system is also critical. Some techniques to 2852 
concentrate the various peptides prior to analysis are recognized to recover the 2853 
larger precursors in different proportions to the smaller peptides, thereby 2854 
introducing error. This is especially an issue for mass-spectrometry or gel 2855 
chromatography. Similarly, there is no tradition of checking the antibodies used 2856 
in immunohistochemistry to determine if they are recognizing POMC precursors 2857 
to the same degree as the peptide to which they have been raised. Much of the 2858 
literature makes statements about the peptides detected, but rarely do reports 2859 
qualify this with mention or measure of other POMC peptides which might also 2860 
be present. 2861 
 2862 
A. Future perspectives on POMC processing in the hypothalamus 2863 
 2864 
Given the significant amount of knowledge gained in the last 20 years about the 2865 
role of POMC in regulating energy balance, it may seem that there is little more to 2866 
unravel. However, this review has highlighted the uncertainty around the 2867 
respective roles of - and -MSH. There is no doubt that loss of the complete 2868 
POMC gene is associated with obesity, however it is more difficult to understand 2869 
the contribution of - and -MSH in patients with mutations in these regions. To 2870 
date, evidence indicates that loss of -MSH rather than -MSH is more likely to 2871 
be associated with an increased risk of obesity, but the mutations reported have 2872 
been in the heterozygous state and number of affected probands remains small. 2873 
The loss of active -MSH in ravenously hungry and overweight Labradors 2874 
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provides intriguing evidence for its function. On the other hand, the inability to 2875 
produce -MSH in rodents points to a redundancy. The comparable potency of 2876 
the two peptides at the MC4R suggests that either peptide could regulate energy 2877 
balance. Therefore it may be that discrimination lies at the level of post-2878 
translational modifications which might generate bioactive -MSH but inactive 2879 
-MSH or vice versa. An ability to measure the relative concentrations of each of 2880 
the bioactive peptides in the vicinity of the receptors in vivo would be invaluable 2881 
but, to date, this remains a very technically challenging procedure. 2882 
 2883 
In addition to the contention around which species of MSH may predominate at 2884 
the MC4R, there still remains uncertainty around the acetylation of -MSH. There 2885 
is conflicting data about whether -MSH or des-acetyl -MSH represents the 2886 
more relevant form in the hypothalamus. N-terminal acetylation is thought to 2887 
increase the stability of peptides, although other reports indicate it depends on 2888 
the type of N-terminal acetylase and may target peptides for degradation. Early 2889 
literature suggests des-acetyl -MSH is the major form in the ARC of the 2890 
hypothalamus. There is a suggestion that the des-acetyl -MSH peptide travels 2891 
within the POMC neurons from the ARC to the PVN and then the N-acetyl 2892 
transferase acts at the neuronal terminals in the PVN just prior to release from 2893 
the neuron. Nevertheless, it is the acetylated form that is thought to be 2894 
biologically active in terms of food intake and the process of acetylation, which is 2895 
regulated by leptin, suggesting that this is a critical step. However, there is also 2896 
controversy about the relative concentrations of its precursors. While -MSH is 2897 
detected at higher concentrations than POMC and ACTH in rat hypothalamic 2898 
extracts, its levels are not regulated by fasting, in contrast to those of its 2899 
precursors. This again highlights some gaps in our understanding of POMC 2900 
processing. 2901 
 2902 
B. Why is POMC present in the circulation? 2903 
 2904 
It is often assumed that hormone precursor molecules will be efficiently 2905 
processed within the cell before release of the small active peptide, but like pro-2906 
insulin, POMC is released into the circulation. There is now good evidence for 2907 
POMC in the circulation, both from normal human subjects and particularly in 2908 
patients with tumors secreting ACTH-related peptides. It is tempting to speculate 2909 
that this is an “overflow” mechanism, occurring in the pituitary corticotrophs. As 2910 
ACTH has to be present in secretory vesicles ready for release at times of acute 2911 
stress, it may be that POMC is produced continuously to supply ACTH, but when 2912 
there is sufficient ACTH, POMC is routed to immature secretory granules and 2913 
released from the corticotrophs in an “overflow” pathway. This would explain 2914 
the data suggesting that the precursors may not be regulated to the same degree 2915 
as ACTH. 2916 
 2917 
C. Are ACTH precursors responsible for the clinical symptoms of 2918 
ectopic ACTH syndrome? 2919 
 2920 
Increased ACTH precursors are frequently used in our lab as a diagnostic tool to 2921 
identify patients with ectopic ACTH syndrome (and those with large pituitary 2922 
corticotroph macroadenomas). In addition, as stated above, most ACTH assays 2923 
 61 
detect the ACTH precursors, but underestimate their true concentrations. 2924 
Therefore it would seem tempting to speculate that the ACTH precursors are the 2925 
cause, at least in part, of the clinical symptoms.  2926 
 2927 
On the other hand, this review has highlighted several reasons why it is difficult 2928 
to make these assumptions. The early studies assessing the bioactivity of POMC 2929 
and pro-ACTH have suggested that these precursors may only have low 2930 
bioactivity at the MC2R. However, with newer approaches to measuring the 2931 
precursors and with the discovery of MRAP, it may be that this evidence needs to 2932 
be revisited. It is also likely that the higher molecular weight precursors will 2933 
have a longer half-life and this might increase their ability to stimulate the 2934 
receptors at the adrenal gland.  2935 
 2936 
In contrast, it is difficult to completely rule out ACTH as the causative agent. This 2937 
is particularly true in those cases of ectopic ACTH syndrome where ACTH 2938 
precursors are high, but ACTH concentrations are normal or slightly elevated. It 2939 
is known that these levels of ACTH, if continuously secreted by a tumor, so that 2940 
they remain elevated at night, can give rise to Cushing’s syndrome. Therefore, 2941 
given these reservations, it is important to continue to improve our 2942 
understanding of the role of ACTH precursors and their processing in Cushing’s 2943 
syndrome.  2944 
 2945 
D. Summary 2946 
 2947 
POMC represents a conundrum in many ways. Is it just an inactive precursor? 2948 
Does it have a role as a relatively stable protein, binding with low affinity to 2949 
receptors? Does the secretion of unprocessed POMC by tumors reflect a relative 2950 
lack of differentiation of the malignant cells? How important is regulation of 2951 
POMC gene expression when the enzymes generating the smaller bioactive 2952 
peptides are also tightly regulated? POMC is certainly an archetypal hormone 2953 
precursor, delivering exquisite physiological control to complex multi-organ 2954 
processes and we need to learn more about it. 2955 
 2956 
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FIGURE LEGENDS 2987 
 2988 
Figure 1: Processing of human POMC in different tissues 2989 
Pro-hormone convertase 1/3 (PC1/3) sequentially cleaves Pro-2990 
opiomelanocortin (POMC) → pro-ACTH → adrenocorticotropic hormone (ACTH).  2991 
 In hypothalamus, skin, and pars intermedia of the pituitary ACTH is further 2992 
cleaved by PC2 to produce ACTH (1-17) and corticotropin-like intermediate 2993 
peptide (CLIP). Carboxypeptidase E (CPE) then cleaves basic amino acid residues 2994 
from the C terminal, allowing amidation by peptidyl α-amidating 2995 
monooxygenase (PAM) to form des-acetyl α-MSH (DA-α-MSH). N-2996 
acetyltransferase (N-AT) finally acetylates DA-α-MSH to produce α-MSH. PC2 2997 
cleaves β–lipotropic hormone (β-LPH) to β-endorphin (β-EP) and γ-LPH, which 2998 
is further cleaved to -MSH. The N-terminal peptide, N-POMC, has dibasic amino 2999 
acids at the N-terminal of γ-MSH which are thought to be cleaved by PC2.  3000 
 3001 
Figure 2: Species differences in the cleavage sites of POMC 3002 
The Pomc gene has three exons with the translation start site in exon 2. 3003 
Prohormone convertases (PC) cleave at dibasic sites comprising lysine (K) and 3004 
arginine (R). These sites are generally well conserved, but occur at different 3005 
amino acid numbers in the human, mouse/rat and dog sequences. The absence of 3006 
pairs of dibasic amino acids at the relevant sites in the rat/mouse POMC 3007 
sequence predicts that γ-MSH  and -MSH will not be produced.  3008 
 3009 
Figure 3: POMC processing in neurons 3010 
POMC processing begins in the TGN which is based in the cell body in the ARC. 3011 
Very little is known about the sites of processing as the peptides move to the 3012 
neuronal terminals in the PVN. There is some suggestion that N-terminal 3013 
acetylase (N-AT) converts des-acetyl α-MSH (des-α-MSH) to α-MSH at the 3014 
neuronal terminal such that α-MSH is released to activate MC4R and decrease 3015 
food intake (258, 312). POMC can also be processed in the NTS, where less is 3016 
known about the processing and des-acetyl -MSH and acetylated -endorphin 3017 
are the prominent peptides generated. ARC is arcuate nucleus, PVN is the 3018 
paraventricular nucleus, 3V is third ventricle, NTS is Nucleus Tractus Solitarius. 3019 
 3020 
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Figure 4: Alternative secretory pathways for precursors and POMC-derived 3021 
peptides. 3022 
POMC is either stored in immature secretory granules (ISG) and released by 3023 
constitutive secretion or processed and peptides stored in mature secretory 3024 
vesicles (MSG) before release by regulated secretion. The anterior pituitary has 3025 
PC1/3 and therefore processing is more limited than in the hypothalamus and 3026 
skin which have both PC1/3 and PC2, and other enzymes, giving rise to further 3027 
post-translational processing that results in the MSH peptides. 3028 
 3029 
Figure 5: POMC processing generates numerous functional peptides.  3030 
The primary roles of the different functional peptides cleaved from POMC are 3031 
shown 3032 
 3033 
Figure 6: Regulatory processes for secretion of POMC and its peptides.  3034 
(A) POMC moves from the TGN to immature secretory granules (ISG) and is 3035 
secreted from cells by constitutive secretion. PC1 processing cleaves POMC to 3036 
produce ACTH which is stored in dense core secretory granules (DCSGs) before 3037 
secretion is stimulated. (B) On stimulation, α-MSH and possibly ACTH is released 3038 
from the cells in the hypothalamus/skin/pars intermedia of the anterior lobe of 3039 
the pituitary. (C) Acute CRH stimulation in the anterior pituitary causes the 3040 
release of ACTH. POMC is also released but not subject to stimulation. (D) Long-3041 
term CRH stimulation upregulates the Pomc gene and release of ACTH. (E) 3042 
Glucocorticoids can inhibit ACTH secretion in an acute, non-genomic manner in 3043 
the anterior pituitary. (F) Chronic exposure to glucocorticoids inhibits POMC 3044 
transcription and ACTH release. Adapted from (384) 3045 
 3046 
Figure 7: ACTH precursor secretion in ectopic ACTH syndrome 3047 
Pituitary tumors have excess production of ACTH while ACTH precursors are 3048 
released from ectopic (non-pituitary) tumors. The increased ACTH related 3049 
peptides lead to increased cortisol production 3050 
 3051 
Figure 8: Concentrations of ACTH precursors in different patient groups.  3052 
The ranges relate to concentrations of ACTH precursors in blood samples from 3053 
different groups of patients. The superscript numbers indicate the following 3054 
references 1(89), 2(385), 3(150)), 4(278), 5(337), 6(285).  3055 
 3056 
Figure 9: Monoclonal antibody based assays to POMC derived peptides.  3057 
(a) The monoclonal antibodies (MAbs) bind to specific epitopes on the peptides. 3058 
A pair of antibodies is required for a two-site assay. This gives specificity. (b) 3059 
The ACTH precursor assay has one MAb specific for the ACTH region and one 3060 
within the N-POMC region. (c) The ACTH assay uses a pair of MAbs which 3061 
recognise the N- and C-regions of ACTH. They can recognise these epitopes in 3062 
POMC but only bind about 2% of the precursors 3063 
 3064 
Table 1: Melanocortin receptors and ligand selectivity 3065 
 3066 
 3067 
 3068 
 3069 
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Figure	2:	Species	differences	in	cleavage	sites	of	POMC		
Figure	3:	POMC	processing	in	neurons	
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Figure	4:	Alterna/ve	secretory	pathways	for	precursors	and	POMC-derived	pep/des.	
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Table	1:	Melanocor.n	receptors	and	ligand	selec.vity	
Melanocor.n	
Receptor	 POMC	derived	pep.des	
MC1R	 α-MSH	=	ACTH	>	β-MSH	>	γ-MSH	
MC2R	 ACTH	only	
MC3R	 α-MSH	=	β-MSH	=	γ-MSH	=	ACTH		
MC4R	 α-MSH	=	ACTH	>	β-MSH	>	γ-MSH	
MC5R	 α-MSH	>	ACTH	>	β-MSH	>	δ-MSH	
α-MSH	
↓	Food	intake	
↑	skin	pigmenta1on	
	
Figure	5:	POMC	processing	generates	numerous	func;onal	pep;des.		
		
β-MSH	
↓	Food	intake	
ACTH	
S1mulates	cor1sol	release	
↑	Adrenal	growth	
Pro-opiomelanocor;n	(POMC)	
Low	bioac1vity	at	MCRs	
Pro-ACTH	
Low	bioac1vity	at	MCRs	
β-LPH	
Lipid	mobiliza1on	
β-EP	
↑Analgesia	
Inhibits	gonadotropin	
secre1on	
↑	Food	intake?	
DA-α-MSH	
↓	Food	intake	
N-POMC		
γ-MSH	
Hypertension	
1-48/49	
S1mulate	DNA	
synthesis	and	
hypertrophy	
1-28	
↑	Adrenal	growth	
Figure	6:	Regulatory	processes	for	secre4on	of	POMC	and	its	pep4des.		
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Figure	7:	ACTH	precursor	secre'on	in	ectopic	ACTH	syndrome	
Figure	8:	Concentra0ons	of	ACTH	precursors	in	different	pa0ent	groups.		
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Figure	9:	Monoclonal	an0body	based	assays	to	POMC	derived	pep0des.		
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